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Abstract

RETINOIC ACID INDUCED 1 GENE ANALYSIS IN HUMANS AND ZEBRAFISH
By Bijal Akshay Vyas, B.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Dr. Sarah H. Elsea
Associate Professor, Department of Human and Molecular Genetics
Department of Pediatrics

Smith-Magenis syndrome (SMS) is a complex mental retardation syndrome
caused by deletion of 17p11.2 region or mutation of the RAI1 gene (retinoic acid induced
1). Individuals with SMS typically exhibit speech and motor delays, mental retardation,
characteristic craniofacial and skeletal anomalies, and a distinct neurobehavioral
xi

phenotype that includes sleep disturbances, stereotypes, and maladaptive and selfinjurious behaviors. RAI1 is thought to be a transcription factor modulating the
expression of genes involved in a variety of cellular functions. Previous studies have
shown the RAI1 gene being induced by retinoic acid (RA), a derivative of vitamin A. RA
plays a significant role in many processes such as immune function, neurogenesis and
reproduction, and deprivation of RA causes craniofacial defects. We hypothesized that
RA could be inducing RAI1 which then acts as a transcription factor in modulating the
expression of multiple genes. To understand the consequences of clinical variation of
RAI1 gene, we performed mutation screening and identified the first case of SMS without
mental retardation. Using a zebrafish model, full-length rai1 gene was cloned and spatial
and temporal expression of rai1 by in-situ hybridization was evaluated and the effect of
RA on rai1 expression was subsequently analyzed. The data show rai1 expression in
forebrain (diencephalon) and midbrain. A rai1 antisense morpholino will eventually be
created to perform knockdown studies and rescue experiments. These studies will help in
determining the significance of the rai1 gene, and its interacting molecular pathways
responsible for growth, development, and behavior.

xii

CHAPTER 1: Introduction

Smith-Magenis syndrome
Smith-Magenis syndrome (SMS, OMIM #182290) is a multiple congenital
anomalies and mental retardation syndrome caused by an interstitial deletion of
chromosome 17p11.2 including the retinoic acid induced 1 (RAI1) gene, or mutation of
RAI1. Patients are diagnosed with SMS by their typical characteristics such as mental
retardation, sleep disturbance, craniofacial and skeletal abnormalities, neurological and
behavioral abnormalities, and ocular and otolaryngological abnormalities.
Approximately 90% of cases have a fluorescent in situ hybridization (FISH) detectable
17p11.2 microdeletion ranging from ~1.5 to 9 Mb, while the remaining 10% have a
mutation in RAI1. Almost all cases are sporadic. The incidence rate of this
neurodevelopmental disorder is estimated to be 1:15,000-25,000 births, but it seems
likely that these figures represent an underestimate (10).
Craniofacial/ Skeletal abnormalities
SMS patients exhibit distinctive craniofacial and skeletal anomalies that include
brachycephaly, a broad square-shaped face, midface hypoplasia, synophrys, upslanting
palpebral fissures, deep set eyes, everted upper lip with tented appearance, micrognathia
1

in infancy, relative prognathism with age (1), brachydactyly, short stature and scoliosis.
Short stature (< 5th percentile) is observed in SMS patients during their childhood but
with time, most individuals reach 10th-25th percentile during adulthood (10, 15). Other
skeletal abnormalities include 5th finger clinodactyly, 2-3 toe syndactyly, polydactyly and
vertebral anomalies. (22, 29, 43)
Neurological/ Behavioral abnormalities
All individuals with SMS show hypotonia in infancy and childhood, motor and
speech delay, and ultimately some degree of mental retardation (usually in the mild to
moderate range). The behavioral phenotype is also very characteristic and includes
twirling objects, hand-wriggling, hyperactivity, attention-seeking, temper tantrums,
outbursts, aggression ( 7, 41) and self-injurious behaviors such as self-biting,
polyembolokoilamania (insertion of foreign objects into body orifices), onychotillomia
(pulling out fingernails and toenails), skin-picking, finger-chewing and head-banging
(10). Specific stereotypes of the syndrome are the spasmodic upper body squeeze or
―self-hugging‖ and the ―lick and flip‖ behavior that is hand-licking and page-flipping (7,
12). Moreover, one of the most telling clinical features is the presence of sleep
disturbances with inverted circadian rhythm of melatonin (36). The sleep problems
experienced by SMS patients include difficulties falling and staying asleep, early
awakenings, excessive daytime sleepiness, daytime napping, snoring, bed-wetting, and
diminished rapid eye movement (REM) sleep (8, 20, 36).
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Ocular/ Otolaryngological abnormalities
Ocular abnormalities such as strabismus, myopia, microcornea, iris abnormalities
are observed in SMS patients. Along with these, otolaryngological abnormalities that
include hearing loss, hoarse deep voice, chronic ear infections and vocal cord nodules
and polyps are also quite common (10, 22). Abnormalities such as hearing loss, which
varies from being mild to moderate, could be a result of the ear infections seen in these
patients (21, 22).
Systemic defects and other manifestations
Other features noted in SMS patients include cardiovascular anomalies, renal
abnormalities, pes-planus (flat feet), hypercholesterolemia, immunoglobin deficiencies
(IgA, IgG and IgE), and dental abnormalities (8, 10, 22). Cardiovascular anomalies seen
in 30% of the SMS patients include ventricular and atrial septal defect, mild stenosis,
tricuspid stenosis, aortic stenosis, pulmonary stenosis, tricuspid and mild regurgitation,
mitral valve prolapse, tetrology of Fallot, and total anomalous pulmonary venous return
(8, 11). SMS patients also reported with renal abnormalities such as enlarged kidneys,
duplication of the collecting duct, ectopic kidneys, kidney stones and urinary tract
infections (8, 22). These individuals have been reported to have dental abnormalities
such as taurodontism and tooth agenesis (45).

Retinoic acid induced 1
Role of the RAI1 gene
RAI1 (Genbank AY172136; OMIM*607642) maps to the central portion of the
17p11.2 region, which is defined as the SMS critical region (Fig. 1). The RAI1 gene is

3

Fig.1 Schematic of chromosome 17. Map of the SMS critical region, including the
RAI1 gene. Deletion of the 17p11.2 region or mutation of the RAI1 gene causes SmithMagenis syndrome.

4

(a)

(b)

Fig.2 Genomic and protein structure of RAI1. (a) The genomic structure of the RAI1
gene which consists of 6 exons, of which 3-6 are coding exons. RAI1 gene is composed
of ~5721 bp. (b) The protein structure of RAI1 composed of 1906 amino acids and
includes a polyglutamine (Poly-Q), polyserine (Poly-S), a bipartite nuclear localization
signal (NLS), and C-terminal plant homeodomain (PHD).
Source: Elsea and Girirajan 2008
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made up of 6 exons, of which 3-6 are coding exons (Fig. 2). The RAI1 gene generates
~7.6 kb mRNA and encodes a 1906 amino acid protein with a molecular weight of 203
kDa (Fig. 2). This gene was first identified in mouse pluripotent embryonic carcinoma
cells (P19). These cells were treated with retinoic acid (RA) which lead to neuronal
differentiation and also induced the upregulation of the Rai1 gene (26). The alignment of
the human RAI1 gene sequence with other mammalian species showed the highly
conserved nature of this gene (15). Comparing human with mouse indicated RAI1 to be a
homologue of the mouse Rai1, sharing 84% identity which suggests that human RAI1
could be induced by RA in similar fashion and this induction contributes towards the
neuronal development seen in SMS.
Furthermore, this gene contains a polyadenylation signal and a large 3‘- UTR.
The RAI1 protein contains a bipartite nuclear localization signal, polyglutamine and
polyserine tracts and a plant homeodomain (PHD)/ zinc finger domain at the C-terminus
(10, 46) (Fig. 2). The polyserine tract at the carboxy terminal is composed of [S]3A[S]8
and is similar to the motifs found in DRPLA and Drosophila hairless genes (10). These
motifs have been shown to be involved in development of the nervous system and also in
transcription of genes (32, 39). The PHD domain of the RAI1 protein is also similar to
the trithorax family of the nuclear proteins which is involved in chromatin remodeling
and regulating transcription. In addition to this, the amino acid sequence motifs such as
bipartite nuclear localization signal and PHD domain are found to be related to the
transcription factor stromelysin-1 platelet derived growth-factor-responsive element
binding protein (TCF20) (10, 39). This suggests that RA could be inducing the RAI1
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gene which then acts as a transcription factor in modulating the expression of genes
involved in a variety of cellular functions (2).

Retinoic acid
Retinoic acid (RA) is a derivative of vitamin A and plays an important role in
cellular

growth,

differentiation,

embryogenesis,

vision,

immune

function and

reproduction (30, 38). Plants and microorganisms synthesize and store carotenoids, a
precursor of vitamin A. Animals obtain these precursors by the intake of plants and
convert them into retinal using retinol dehydrogenases, and then oxidize retinal into RA
irreversibly using retinal dehydrogenases (Raldh) (6).
These RA molecules bind to the transcription factors/receptors known as retinoic
acid receptors (RARs) as they are not capable of binding directly to the gene (38). The
receptors then become activated by the binding of all-trans retinoic acid and this
RA/RAR complex regulate gene expression by binding to short DNA sequences
(enhancer elements) in the vicinity of the target gene (13, 33, 35). This hypothesis was
illustrated in an experiment done by Imai et al. in 1995, where the Rai1 gene was induced
in P19 mouse cells upon RA treatment.

The upregulation of the Rai1 gene and

differentiation of neurons in mice by the induction of RA suggests that RA could be
playing an indirect role in causing neurological features seen in SMS.
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CHAPTER 2: RAI1 variations in SMS patients and refinement

of sequencing methodology

Introduction
Smith-Magenis syndrome was diagnosed in a patient for the first time by Ann
Smith and Ellen Magenis in 1986 (43). This syndrome is caused by an interstitial
deletion of 17p11.2 region or a mutation in the RAI1 gene. The deletion was identified
using a standard cytogenetic Giemsa staining (G-banding) technique. Although with
time, techniques such as fluorescent in-situ hybridization (FISH) came into practice
which made the identification of this deletion possible. With this technique, it was
possible to map the deletions of various sizes on the 17p11.2 region and delineate the
SMS critical region. The size of the deletions seen in SMS patient varies from ~1.5 Mb
to ~9 Mb (48). Approximately, 75% of these patients have a common deletion of ~ 3.7
Mb. The remaining patients have smaller or larger deletions. The SMS critical region
was further delineated to ~650 kb (47) that contained about 25 genes, including RAI1.
Along with this cohort of patients with a detectable 17p11.2 deletion analyzed by
FISH, there were a few patients that were negative for the deletion but exhibited SMS
phenotype. In 1995, Imai et al. had shown upregulation of the Rai1 gene (GT2) and
differentiation of neurons by the induction of RA, suggesting that the absence of RA
8

could be a cause of suppression of the RAI1 gene and the neurological features seen in
SMS. As the RAI1 gene lies in the SMS critical region, it was hypothesized that a
deleterious change of nucleotide in this gene could result in SMS. Several patients with
no 17p11.2 deletion but with SMS features were identified in Slager et al. (2003), Bi et
al. (2004), Bi et al. (2006), Girirajan et al. (2005) and Girirajan et al. (2006), Lily
Truong. (2008), GeneDx, and in the present report (Table 1). These patients were then
analyzed by sequencing the RAI1 gene to detect the variations as compared to the normal
RAI1 sequence. Sequence alignment identified point mutations in all of these patients.
RAI1 mutations are usually de novo as they are not present in the parental samples. If the
mutations identified in SMS individuals are also present in their parents, then they are
considered to be familial changes. Seven cases of familial changes have been previously
identified (Table 2). Although the SMS individuals have inherited the changes
maternally or paternally, there is no expressivity of SMS symptoms in their
mother/father. We are unsure if these nucleotide changes are a result of reduced
penetrance, mosaicism present in the parents, or a mutation in another locus that could be
contributing in causing SMS. Hence, further functional studies are required to address
these questions.
All the mutations identified until now are located on exon 3 of the RAI1 gene.
This exon is the largest exon in this gene and encodes > 98% of the RAI1 protein (Fig.
2a). Any point mutation or microdeletion in RAI1 gene usually results in a frameshift
mutation which produces a truncated and non-functional protein, which is probably
degraded by a post-transcriptional process called nonsense mediated decay. This reveals

9

Table 1. Summary of mutations in the RAI1 gene.
Nucleotide
Change
c.253del19
c.1119delC
c.1449delC
c.1974G>A
c.2773del29
c.2878C>T
c.3103insC
c.3103insC
c.3103delC
c.3103delC
c.2966delAAGA
c.3634A>G
c.3801delC
c.4649delC
c.4685A>G
c.4813A>T
c.4933delGCCG
c.5423G>A
c.5265delC
c.5280C>T

Amino Acid Change
p.Leu85fsX60
p.Ser373fsX65
p.Pro483fsX34
p.Trp658X
p.Val925fsX8
p.Arg960X
p.Gln1035fsX30
p.Gln1035fsX30
p.Gln1035fsX28
p.Gln1035fsX28
p.Lys989fsX38
p.Ser1212Gly
p.Pro1267fsX46
p.Ser1550fsX36
p.Gln1562Arg
p.Arg1604X
p.Ala1645fsX35
p.Ser1808Asn
p.Pro1755fsX74
p.Arg1604X
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Remarks
Deletion/frameshift
Deletion/frameshift
Deletion/frameshift
Nonsense mutation
Deletion/frameshift
Nonsense mutation
Insertion/frameshift
Insertion/frameshift
Deletion/frameshift
Deletion/frameshift
Deletion/frameshift
Missense mutation
Deletion/frameshift
Deletion/frameshift
Missense mutation
Nonsense mutation
Deletion/frameshift
Missense mutation
Deletion/frameshift
Nonsense mutation

Table 2. Summary of familial changes in the RAI1 gene.
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the importance of the functional RAI1 gene and its potential dosage dependent effect that
could result in SMS features.

Materials and methods
Patient ascertainment and samples
Twelve patients exhibiting SMS phenotypes were referred through geneticists
from various parts of the world and their DNA/blood/saliva samples were sent to Dr.
Sarah Elsea‘s laboratory for research purposes. The Institutional Review Board of the
Virginia Commonwealth University approved this study. Informed consent for genetic
testing was obtained from the patient and from the patient‘s parents. A clinical survey
was also requested that covered clinical and physical examination results such as
individual‘s height, weight, head circumference, ENT reports, spine X-ray, podoscope of
hands and feet, immunological tests, echocardiography, and renal ultrasound. Most of
the information regarding the behavioral features was obtained from the parental survey
while the clinical information was based on the geneticist reports. Short stature was
measured relative to their parents or siblings height. If their height measurement was less
than 5th percentile, then the SMS individual was considered to have a short stature. The
algorithm followed for the diagnosis of SMS is illustrated in Fig. 3.
DNA isolation from whole blood
Genomic DNA was extracted from peripheral blood samples using the DNA
mini-kit by Qiagen (Valencia, California, USA). The isolated DNA was quantified by a
spectrophotometer at the absorbance ratio of 260/280.
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Fig. 3. Algorithm used for the diagnosis of SMS. A flow chart illustrating the procedure used for the diagnosis of SMS.
Patients with clinical suspicion of SMS were evaluated for 17p11.2 deletions. Non-deletion cases were referred for RAI1
mutation screening and if mutations were identified, their parental samples were evaluated to define the mutation as de novo or
familial.
13

DNA isolation from saliva
Genomic DNA was isolated from patient saliva samples using the protocol for
manual purification of DNA from saliva by Oragene ®. The isolated DNA was measured
by a spectrophotometer at the absorbance ratio of 260/280.
Polymerase chain reaction
Polymerase chain reaction (PCR) was carried out on patient DNA by using
overlapping primers, spanning exons 3-6 of the RAI1 coding region, as shown in Table 3.
PCR reactions contained the following: 1X PCR buffer (50 mM KCl, 10 mM Tris-HCl
and 1.5 mM MgCl2), 20 pmol of each forward and reverse primers (Table 3), 200 µM
dNTPs, 1 U of Taq DNA polymerase, and 50 ng genomic DNA in a total reaction volume
of 25 μl. Cycling conditions were as follows: initiation at 94°C, 5 min, followed by 35
cycles of denaturing at 94°C, 1 min, annealing at 55-66°C, 1 min (Table 3), and extension
at 72°C, 1 min, followed by a final elongation step at 72°C for 10 min. PCR products
were run on a 1% agarose gel to assess quality. PCR products were either purified by gel
extraction using the Qiagen Gel Extraction kit (Qiagen Inc, Valencia, California, USA) or
by digesting with 2 U of shrimp alkaline phosphatase (SAP) and 10 U of exonuclease I
(Exo) for a combined 7 μl reaction volume (USB Corporation, Cleveland, Ohio, USA) at
37°C for 30 min, followed by an 80°C incubation for 15 min to inactivate ExoSAP-IT.
Sequencing
DNA sequencing of these products was performed at the Virginia Commonwealth
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Table 3. PCR primers for RAI1 sequencing.*
Exon
Start E3
3
3
3
3
3
3
3
end E3
4
5
6+3'UTR

Forward primer

Reverse primer

SHE323:
TCTGAGGCAAAAGGAAGTGG
SHE505:
CCCGAGTCATGCAGTCTTTT
SHE507:
GGTCCAGAATCTTCATGCCTA
SHE509:
CTGCCAGGGTCAACAGCAAC
SHE511:
AGGAGGACCTGGAAGCTGAG
SHE513:
GCTCCAAGACCAAGGAGACA
SHE515:
GGCCTCTCCTGGTAATCCTC
SHE335:
AAACCGAGGCCTTCACATC
SHE339:
CTACCCTGAACACTGCCTCC
SHE527:
CCAGCCTGTAAAGCTTGAGG
RA46:
GGAGTGGAGTGGAGTGTGGAGG
SHE345:
ACTGTGAAGTCCGAGGTCGT

SHE324:
GACTGGGAATGCTGAGGAAA
SHE506:
TGGTAATGGAGGGTTTCCTG
SHE508:
CATGTCGTCAGGAGAGGTCA
SHE510:
CTCCTCCTCAGCTTCCAGGT
SHE512:
GTGACCGAAGGATCATGGAG
SHE514:
GCCTCGGTTTTGAAACAGTCA
SHE516:
GCAGCAAACAAGGCAAGAGGT
SHE336:
CACACTCGGGACCTTTGAGT
SHE340:
AGAGGCAATGGAGACAGGAA
SHE528:
GGAATGCCTCATTTCCATGT
RA45:
GGACTGTGAAGGAGGTGCGAG
SHE346:
GACTGGAAAGGGGACAAACA

*Primers cover the coding region of RAI1 isoform a.
+
Amplification requires Invitrogen® PCR enhancer.
PCR, polymerase chain reaction; Ann. temp., annealing temperature; UTR, untranslated region.
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Product Ann.
size (bp) temp.
770

62ºC

925

60ºC

947

62ºC

995

64ºC

861

66ºC

910

62ºC

1010

64ºC

964

60ºC

887

60ºC

362

62ºC

310

64ºC

766

62ºC+

University Sequencing Core by cycle sequencing. Purified PCR product (10 ng/μl), 20
ng/μl of each primer, and 4 μl of the ABI Prism terminator cycle sequencing ready
reaction mix (Applied Biosystems, Foster City, California, USA) were combined in 10 μl
final volume for 25 cycles. The samples were then cleaned with filter paper, resuspended
in formamide, denatured at 95°C for 2 min, and loaded onto an ABI3730 genetic analyzer
(Applied Biotech/Hitachi).
Sequence alignment and analysis
The chromatogram results were received from the sequencing core and analyzed
by comparing patient sequencing results with the normal RAI1 sequence visually by
looking for heterozygosity and sequence quality and also by aligning the patient sequence
with the RAI1 mRNA database sequence at the NCBI and Genome Browser using Clustal
X and Bioedit. Forward and reverse primer sequencing results were used to confirm the
presence of any variation identified in the patient. Parental samples were evaluated for
any identified mutation.

Results
Clinical and molecular features of patients with RAI1 variations
Twelve patients with negative FISH results for 17p11.2 deletion were tested for
RAI1 variations such as SNPs and mutations by sequencing of the RAI1 gene. Most of
them were identified with SNPs that were known and listed in the database. Four of
these patients were identified with novel SNPs, and two of these SNPs were located in
the intronic region and are of unknown significance (Table 4). These polymorphisms
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have been identified in at least 1% of the normal population and are considered to be nondisease causing. However, we are unaware of their potential effect on SMS phenotype
and hence, further studies have to be performed to study their role in SMS. Besides the
identification of novel SNPs, we also identified the first SMS patient with an RAI1 gene
mutation that does not show frank mental retardation. Detailed molecular and clinical
information of these patients are mentioned below.

Table 4. Novel RAI1 mutations and polymorphisms identified in present study.

Patient
SMS339

Novel
Mutation

Amino acid
change

c.2966delAAGA p.Lys989fsX38

SMS349

Novel
SNPs

Amino acid
change

c.2773C>A p.Val925Ile
c.3357C>T p.Ser1119Ser

SMS346

c.571022G>T

N/A

SMS351

c.571049C>T

N/A

SMS331
SMS331 is a 7 year old male of African American descent and had been evaluated
since he was 17 months old. He exhibited SMS features such as sleep disturbance,
mental retardation, speech delay, development delay, hypotonia, broad nasal bridge,
upturned nose, tented upper lip, strabismus, vision impairment and chronic ear infections.
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His self-injurious behavior included head-banging, face-slapping and self-biting. At age
of 17 months, his weight was 21.3 kg and height was 113.2 cm, which is ~ 75 th percentile
of weight/height scale.
Laboratory findings show normal karyotype (46 XY), negative fragile X studies,
normal FISH for del(17)( p11.2) and normal aCGH. RAI1 sequencing identified four
polymorphisms, three of them were in heterozygous state and all of them were reported
in the SNP database (Table 5). These nucleotide changes were not deleterious and
therefore, non-disease causing mutations. No other abnormalities in the RAI1 gene were
identified in this patient.
SMS332
SMS332 is 11 year old Caucasian female with a history of cognitive impairment,
behavioral problems, and seizures. She was born at 37 weeks gestation by vaginal
delivery with a birth weight of 5 pounds; 10 ounces (25th- 50th percentile), a birth length
of 19 inches (50th – 75th percentile), and a head circumference of 12.5 inches (10 th- 25th
percentile). She had suffered from jaundice after birth. Her behavioral problems included
polyembolokoilomania, repetitive movements, food obsession and sleep disturbances.
She also exhibited other features consistent with SMS such as midface hypoplasia, a
broad, square face, tented upper lip, mental retardation, speech and motor delay.
Her family history was quite complicated. She had two brothers and the older
one was diagnosed with pervasive developmental disorder. The patient‘s mother had a
sister whose son was diagnosed with Down syndrome. Her grandmother committed
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Table 5. Known polymorphisms identified in present study.
Poly Q
c.269G>C c.493C>A c.837G>A

SMS331

c.1992G>A

c.4311T>C c.4530C>T

2

SMS332

1

SMS336

1

SMS339

2

1

1

1

1

1

1

2
2

1

1

c.5601T>C

Allele

Allele

1

2

1

14

14

1

13

14

13

14

13

13

14

14

10

13

1

2

SMS343
SMS344

c.5334G>A

2
1

1

2

SMS345

2

2

14

14

SMS346

2

2

14

14

1

1

13

14

1

12

13

SMS348

1

1

1

SMS349

2

SMS351

1

2

14

14

1

1

13

13

SMS356

1

1

1

1

1 – SNPs present in the heterozygous state
2 – SNPs present in the homozygous state
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suicide and had a history of depression. Her maternal aunt was reported with myasthenia
gravis. The patient‘s maternal grandfather had 2 brothers who died from heart problems.
Her father‘s sister died of diabetes and renal failure. Her paternal uncle had a son with
autism.
Laboratory data included normal female karyotype, normal FISH for
del(17)(p11.2), normal aCGH and negative result for Prader-Willi and Angelman
syndrome (tested by methylation specific PCR for SNRPN gene). Mutation screening
analysis identified six polymorphisms in SMS332, and all of them were in heterozygous
state (Table 5). No other RAI1 variations were identified in this patient‘s sequencing
results.
SMS336
SMS336 is 5 year old female of Caucasian descent. She was evaluated at 3.5
years of age due to her unusual growth delay features. She was born at 37 weeks via
normal spontaneous vaginal delivery to her 21 year old G 1Po mother. During pregnancy,
her mother had suffered from frequent UTIs, hypertension, group B strep and decreased
movement towards the end of pregnancy. Patient had experienced multiple episodes of
otitis media which affected her hearing, and she required the placement of bilateral
myringotomy tubes.
aggressiveness,

She exhibited some SMS features such as sleep disturbances,

language

delay,

temper

tantrums,

licking

her

hands,

and

polyembolokoilomania. At age 3, height (35.4 inches) and weight (28 pounds) were
below the 5th percentile. Her physical features included frontal bossing of the forehead,
up-slanted eyes and up-turned nose.
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Laboratory data included a normal karyotype. RAI1 sequencing identified five
polymorphisms, and four of them were in heterozygous state (Table 5). Additional
aCGH studies revealed a duplication of 4p16.1 region.
SMS339
SMS339, referred for genetic evaluation at 14 years of age, is a female of
Caucasian descent (both parents originate from South Italy) (Fig. 4 and 5). She was the
second child of healthy non-consanguineous parents, and she had a healthy female
sibling. Her parents had experienced three episodes of spontaneous abortion, all during
the 1st trimester of gestation. Due to the history of recurrent miscarriages, karyotype
analysis was performed on her parents, and results were normal. The family history was
otherwise unremarkable.
The patient was born at term by normal vaginal delivery. Birth weight was 3,660
g (75th centile), length 50.5 cm (25-50th centile) and OFC 35 cm (50th centile). Apgar
scores were 8 at 1 min and 9 at 5 mins. She had mild hypotonia during neonatal period
and early infancy but showed normal motor development. Daytime continence was
achieved at 5 years, and nocturnal enuresis persisted until the age of 6. The patient
suffered from recurrent episodes of acute otitis media until 6 years of age, when a
tonsillectomy was performed. At age 7 years, an audiometric evaluation excluded the
presence of hearing loss. At age 10 years, an episode characterized by jerking
movements of the upper and lower extremities was interpreted as febrile convulsions.
The body temperature was 39°C, and subsequent EEG tests showed no abnormalities. At
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the age of 11 years, she underwent orthodontic treatment to resolve dental crowding. She
attained menarche at 13 years with regular periods since then.
Evaluation at age 14 years revealed a broad face, bushy eyebrows with mild
synophrys, upslanting palpebral fissures, full-tipped nose, mild retrognathia, hoarse
voice, dry skin, overeating and mildly overweight (body mass index = 25.9), tricuspid
regurgitation, and a history of constipation and recurrent urinary tract infections. Her
body weight fell between 75th and 90th centile (62.5 kg), height between 10th and 25th
centile (155.4 cm), and head circumference was at +1.2 standard deviations (55.8 cm).
Fig. 4 shows her SMS features observed since childhood, and Fig. 5 (A-D) shows whole
body pictures and the facial appearance of the patient at age 14 years. Skeletal anomalies
included brachydactyly of fingers and especially toes, proximal cutaneous syndactyly of
toes 2-3 (Fig. 6A-C), pes planus (Fig. 6D), and dorsolumbar scoliosis (Fig. 6E). Scoliosis
was diagnosed at 8 years of age and became more severe over time. The compliance of
the patient with the physiotherapy was very low, and she firmly refused to wear the
orthopedic brace.
The patient had been evaluated by psychologists on several occasions using the
Wechsler Intelligence Scale for Children (WISC-R). At 10 years, 9 months of age, her
IQ was 82, while at 11 years, 8 months of age, the IQ was 78. No differences in verbal or
performance IQ were noted. However, a repeat examination at 11 years, 10 months
revealed a total IQ of 91, with verbal IQ at 100 and performance IQ at 84. At the present
age of 17 years, the patient was again evaluated by the WISC-R and had a total IQ score
of 76 with no differences in verbal or performance IQ; however, the psychologist noted
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significantly reduced motivation and collaboration in this examination with concerns that
the test results did not support her true abilities. Despite some learning disabilities, a
certain weakness in sequential processing, and poor short-term memory, she was able to
attend school until the age of 12 years without the help of dedicated persons. Other
neurobehavioral features included weak relational and social skills, tendency to depressed
mood, obsessive thinking, stereotypies, and maladaptive and self-injurious behaviors,
which worsened with age (especially since the onset of puberty). The obsessive thinking
consisted of constant fear to die, to be abandoned, and to have been adopted. The
maladaptive behaviors included temper tantrums, disobedience, impulsivity, verbal
aggressiveness, attention-seeking, and prolonged crying. She showed self-abusive
behaviors such as skin-picking of the legs, nail-yanking, self-hugging,
polyembolokoilamania, cutting locks of her own hair, tearing away her eyebrows, writing
or painting the skin, mouthing of hands and objects, and grinding of the teeth. Moreover,
the patient had significant sleep disturbance, which consisted of difficulties falling asleep,
prolonged night-time awakenings, and excessive daytime sleepiness since the age of 1
year.
The patient‘s karyotype (high resolution G-banding) was 46, XX. Genetic testing
for fragile X syndrome (GC-rich PCR and Southern blot analysis) and molecular
cytogenetic analysis for the detection of SMS deletions (FISH, Cytocell probe) gave
negative results. Screening for variations in the RAI1 coding region identified a
significant nucleotide change in exon 3 that included a deletion of 4 bp starting at
nucleotide 2966 (Fig. 7). This heterozygous novel deletion resulted in a frameshift
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A

D

B

C

E

F

Fig. 4. The changing face of SMS339. Smith-Magenis syndrome (SMS) phenotype
observed in SMS339 since childhood. A. 7 months old. B. 3 years old. A.-B. Note broad
forehead, upslanted palpebral fissures, open mouth posture, tented upper lip, and fulltipped and up-turned nose. C-D. Note broad nasal bridge. E. Note mild brachydactyly.
F. 10 y, note broad nasal bridge and full lips.

24

Fig. 5. Photos of SMS339 at age 14 years. A.-B. Whole body pictures of the patient.
(A) frontal view, note truncal obesity, lateral inclination of the trunk due to scoliosis, and
genu valgum; (B) side view, note again the truncal obesity and the lumbar hyperlordosis.
C.-D. Facial appearance at age 14 y. (C) side view, note the mild retrognathia and the
cervical kyphosis. (D) frontal view, note broad and coarse face, bushy eyebrows with
mild synophrys, and full-tipped nose.
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Fig. 6. Clinical features observed in SMS339. A.-B. Hands of the patient at age 14 y,
note the broad palm and the mild brachydactyly. C. Feet of the patient at age 14 y, note
the marked brachydactyly, proximal cutaneous syndactyly of toes 2-3, toenail hypoplasia,
and mild hallux valgus. D. Plantar view on podoscope showing pes planus and
brachydactyly. E. X-ray images showing dorsal scoliosis of the spine.
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SMS339

c.2966delAAGA

CCCATC GCAAAGAGCCT GTGC
C C C A T C G C A A A G A A A GA G C C T
Normal

Fig. 7. RAI1 mutation analysis in SMS339. Top: An electropherogram of both
mutated and normal alleles from the patient, SMS339, is shown. The patient carries a 4
bp deletion (AAGA) starting at nucleotide position 2966 on one RAI1 allele. This
mutation causes a frameshift and truncation of the RAI1 protein. Bottom: normal RAI1
sequence.
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Table 6. RAI1 variations in SMS339.

Nucleotide change* Amino acid change

SNP ID

2966delAAGA

Frameshift/protein truncation

Novel mutation

p.Gly90Ala (homozygous)
p.Pro165Thr (homozygous)
p.Gln279Gln (homozygous)
p.Val925Ile (heterozygous)
(PolyQ)13

SNP 3803763
SNP11649804
SNP 11078398
Novel SNP

Polymorphisms
c.269G>C
c.493C>A
c.837G>A
c.2773G>A

PolyQ tract

*DNA changes with nucleotide number starting from the ATG in the coding region.

mutation leading to misincorporation of 38 amino acids and truncation of the RAI1
protein. Parental DNA analyses were normal. This de novo mutation was consistent with
the diagnosis of SMS.
The patient also carried several RAI1 polymorphisms, including one novel SNP
(Table 6). Out of the four polymorphisms identified in this patient, three were in the
homozygous state and have been reported in the SNP database (Table 5). In addition, 13
polyglutamine repeats were present on each allele.
SMS343
SMS343 is a female patient of Caucasian descent referred for mutation screening
of the RAI1 gene. FISH analysis of the 17p11.2 region was negative by report. RAI1
mutation screening identified one known polymorphism in the homozygous state located
in the exon 5 region (Table 5). In addition to this SNP, 14 polyglutamine repeats were
present on each allele. This patient was homozygous throughout the exons, which
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suggests the possibility of an internal deletion of the gene which is non identifiable by
sequencing. Hence, additional studies such as aCGH should be performed on this patient
sample to detect the real cause underlying these features.
SMS344
SMS344 is a 9 year old Caucasian female who was evaluated by geneticists
between the ages of 4-8. She was born at 42-weeks gestation and weighed 7 pounds 4
ounces. At the age of 8, she weighed 92.2 kg (> 97 th percentile), her height was 154 cm
(> 97th percentile) and head circumference was 58 cm. She had experienced precocious
puberty at the age of 7 and had suffered from severe obesity. She exhibited SMS features
such as short, square shaped forehead, deep set eyes with horizontal palpebral fissures,
prominent nasal bridge, small upturned nose, strabismus, hearing loss, speech and
developmental delays.

Some of other features included high-arched palate, sloping

shoulders and mild waddling gait.
Laboratory data included a normal karyotype, negative FISH for 15q and17p11.2
deletion, Fragile X and Prader-Willi/Angelman syndrome and normal chromosomal
microarray. RAI1 mutation screening identified three known polymorphisms, with two of
them in the heterozygous state (Table 5). No other deleterious nucleotide changes were
identified in this patient.
SMS345
SMS345 is a Caucasian male patient exhibiting clinical signs of SMS. FISH
analysis of 17p11.2 region as well mutation screening of RAI1 gene did not identify any
deletion.

This patient carried two non-disease causing polymorphisms, both in the
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homozygous state (Table 5). In addition, 14 polyglutamine repeats were present on each
allele. This patient was homozygous throughout the exons, which suggests the possibility
of an internal deletion of the gene which is non identifiable by sequencing. Hence,
additional studies such as aCGH should be performed on this patient sample to detect the
real cause underlying these features.
SMS346
SMS346 is 12 year old male of Caucasian descent, who was evaluated at age of
11 due to his history of developmental delay and dysmorphic features. In addition to
these features, the patient also had some other features consistent with SMS such as
aggressiveness, self-injurious behaviors including head-banging and hand-flapping, sleep
problems, midface hypoplasia, tented upper lip, brachydactyly, and seizures. At the time
of evaluation, his height was 127 cm (< 5th percentile), his weight was 48 kg (> 97th
percentile) and head circumference was 54.5 cm.
Laboratory studies included negative results for Down syndrome and 17p11.2
deletion by FISH and normal aCGH. Sequencing of the RAI1 gene identified four
polymorphisms and 14 polyglutamine repeats on each allele.

Three of the

polymorphisms were located in the exonic region and two of these three were present in
homozygous state (Table 5).

The fourth polymorphism (c.5710-22G>T) present in

heterozygous state was identified in the intronic region and is of unknown significance.
Although this novel nucleotide change may cause alternate splicing of the RAI1 gene
which would disrupt a functional protein domain, additional studies are required to
confirm this hypothesis.
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SMS348
SMS348 is 12 year old half Caucasian, quarter African-American and quarter
Japanese male, who was born at 32 weeks gestation with a weight of 6 pounds 12 ounces.
Since early childhood, he had suffered from behavioral disturbances, sleep problems,
obesity, ear infections and speech delay. He was diagnosed with bipolar disorder and had
been on medications which might have contributed to his obesity.

The physical

examination at the age of 11 showed his weight as 79kg (> 95th percentile), his height as
152 cm (50th – 90th percentile) and head circumference as 55 cm. He also exhibited other
features such as broad, square face, midface hypoplasia, broad nasal bridge, tented upper
lip, flat face, synophyrs and brachydactyly that were also consistent with SMS. Family
history was significant as the patient‘s father and two of his paternal half-siblings had
bipolar disorder and mother had been diagnosed with Charcot-Marie-Tooth disease type
1A (CMT1a).
Laboratory data included normal karyotype and negative result for Fragile X
syndrome. Although aCGH and RAI1 mutation screening ruled out SMS, the patient was
identified with duplication of chromosome 17p12 region that included PMP22. This
finding is diagnostic for CMT1a and is consistent with the CMT1a diagnosis in patient‘s
mother. RAI1 mutation screening identified five known polymorphisms, and all of them
were present in the heterozygous state (Table 5).
SMS349
SMS349 is 19 year old male of Latvian descent with features consistent with
SMS. His craniofacial features included midface hypoplasia, brachycephaly, frontal
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bossing, broad nasal bridge, down turned upper-lip, up-slanting eyes and prognathism.
His ocular/otolaryngological abnormalities included strabismus, myopia, and hoarse
voice. He exhibited some other manifestations such as dental abnormalities, kidney
abnormalities, obesity, pes planus, scoliosis, developmental delay, sleep disturbance and
self-injurious behavior (nail yanking).
Laboratory data included normal aCGH and sequencing of the RAI1 gene which
identified four polymorphisms and three of them were in heterozygous state (Table 5).
One of the four polymorphisms was novel and not listed in the NCBI SNP database. No
other studies have been performed on this patient sample.
SMS351
SMS351 is 4 year old Caucasian male with broad nasal bridge, down-turned
upper lip, brachydactyly, frequent ear infections, sleep disturbance, developmental delays
and self injurious behaviors such as polyembolokoilomania, self-biting, and head banging
in addition to other features consistent with SMS. He was evaluated at the age of 3, and
his clinical examination shows that his weight was 17 kg, height was 95.4 cm and head
circumference was 51.2 cm.
Laboratory findings included negative 17p11.2 deletion by FISH and normal
aCGH results.

Mutation analysis on the RAI1 gene identified three polymorphisms

(Table 5). Two of the polymorphisms were known and located in the exonic region, and
one of these two SNPs was in homozygous state. Although the third polymorphism was
novel and located in the intron 5 region, this variant was present in both his parents.
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SMS356
SMS356 is 11 year old female of Austrian descent with features consistent with
SMS including neurological features (sleep disturbance, mental retardation, hypotonia,
speech and motor delay), craniofacial features (brachycepahly, midface hypoplasia,
broad-square face, and short stature) behavioral features (self-hugging) and self-injurious
features (polyembolokoilomania).
Laboratory results included negative FISH for 17p11.2 deletion. On performing
RAI1 mutation screening, we identified five heterozygous polymorphisms, all reported in
the SNP database (Table 5).

Besides these changes, no other abnormalities were

identified in SMS356.

Comparison between mutation and non-mutation cases
We compared thirty-two clinical features commonly associated with the RAI1
mutation cases to the cohort of non-mutation cases (Table 7). All features were scored as
present (+), absent (-) or data not available (N) (data not shown). These scores were then
recalculated to obtain the percentages and compared with each other. The results (Table
7) indicated that all features were consistent between the two groups. These features
included craniofacial/skeletal characteristics such as synophyrs, midface hypoplasia,
tented upper lip, scoliosis and short stature. Neurological/behavioral similarities included
mental retardation, developmental delay, hypotonia, sleep disturbance, self-hugging and
seizures. Other features that showed consistency included self injurious behavior such as
head-banging/skin picking/finger chewing; ocular abnormalities such as strabismus and
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myopia; otolaryngological abnormalities such as chronic ear infections and hearing loss;
and lastly, pes planus (flat feet) and dental anomalies. Not many RAI1 mutation patients
have been reported with cardiovascular anomalies; SMS339 from present study was one
of the exceptions. There were no significant differences that existed between the
mutation and non-mutation cases and hence, their referral for RAI1 sequencing was right.

Refine the sequencing methodology
RAI1 is a large gene consisting of 6 exons, of which 3-6 are coding exons (Fig.
2a). These coding exons encode a 1906 amino acid protein with the molecular weight of
203 kDa. Out of four coding exons, exon 3 is the largest exon composed of 5580 bp
nucleotides and encodes > 98% of the protein. Exons 4, 5 and 6 are comparatively
smaller exons composed of 93 bp, 49 bp and 12 bp respectively. Sequencing of the RAI1
gene with twelve sets of overlapping primers was a tedious, time-consuming and
expensive process. To make the sequencing methodology time- and cost-effective, the
protocol was refined (Appendix A). Two rounds of sequencing with different sets of
primers were planned (Fig. 8). The first round of sequencing included PCR amplification
with primers (e.g. forward primer of 1st set and reverse primer of the 2nd set) covering big
fragments (~ 2 kb) of the coding region and the amplimers sequenced with forward
primer of 1st set and reverse primer of the 2nd set. This process saved time and cost of
performing two PCR amplifications and sequencing with two sets of forward and reverse
primers. If and only if the first round of sequencing did not cover the entire region, then
it was followed by second round of sequencing which included individual sets of primers
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Table 7. Phenotypic comparison between mutation and ‘SMS-like’$ cases.
SMS
Features
Gender (Male)
Craniofacial/Skeletal
Brachycephaly
Midface hypoplasia
Broad, square face
Tented upper lip
Prognathism (relative to age)
Synophrys
Brachydactyly
Short stature (<5th centile)
Scoliosis
Neurological/Behavioral
Mental retardation
Speech delay
Motor delay
Hypotonia
Sleep disturbance
Self-hugging
Seizures
Overeating
Self-injurious behavior
Head-banging
Skin picking/finger-chewing
Onychotillomania
Polyembolokoilomania
Ocular abnormalities
Strabismus
Myopia
Otolaryngologic
Chronic ear infections
Hoarse, deep voice
Hearing loss
Other manifestations
Cardiovascular anomalies
Pes planus
Renal anomalies
Dental anomalies
Overweight/Obese

% Nonmutations$
(n=11)
54 (n=11)

% RAI1mutations#
(n=14)
57 (n=14)

Fisher's exact
test
(p-value)
1

67 (n=9)
78 (n=9)
78 (n=9)
67 (n=9)
34 (n=3)
45 (n=9)
60 (n=5)
33 (n=9)
50 (n=8)

91 (n=11)
82 (n=11)
92 (n=12)
75 (n=12)
87 (n=8)
33 (n=12)
73 (n=11)
25 (n=12)
33 (n=12)

0.28
1
0.55
1
0.15
0.67
1
1
0.65

100 (n=9)
100 (n=9)
100 (n=9)
57 (n=7)
100 (n=9)
50 (n=8)
43 (n=7)
100 (n=4)

86 (n=14)
100 (n=14)
100 (n=14)
67 (n=12)
100 (n=14)
77 (n=13)
33 (n=12)
87 (n=8)

1
1
1
1
1
0.34
1
1

45 (n=9)
50 (n=6)
37 (n=8)
62 (n=8)

77 (n=13)
80 (n=10)
69 (n=13)
77 (n=13)

0.19
0.30
0.20
0.63

57 (n=7)
75 (n=4)

45 (n=11)
64 (n=11)

1
1

50 (n=8)
50 (n=4)
37 (n=8)

75 (n=12)
83 (n=12)
27 (n=11)

0.36
0.24
1

0 (n=7)
75 (n=4)
12 (n=8)
62 (n=8)
86 (n=7)

17 (n=12)
62 (n=8)
10 (n=10)
67 (n=9)
87 (n=8)

0.5
1
1
1
1

(N) Information not available. # Includes previous Elsea lab cases + new mutation case.
$
Includes non-mutation cases from present study.
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covering an approximately 1 kb region of the coding exons and then sequencing with the
forward or reverse primers that covered the remaining region of the exons. In addition to
this, new internal primers were also designed to check for novel SNPs or for sequencing
for the remaining uncovered region. Along with the new primers, novel SNPs and
mutations have been added to the RAI1 genomic sequence used for the sequence
alignment and analysis (Appendix B). This new protocol of sequencing RAI1 gene has
greatly improved the screening technique for mutation analysis by making the process
faster and cost effective.

Fig. 8 Schematic explaining the two rounds of sequencing. The first round includes PCR
amplification with SHE 323/324 set covering larger fragments. The second round includes
PCR amplification with individual sets of primers (SHE323/324 and SHE325/326).
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Discussion
Identification of mutations and polymorphisms
We reported twelve patients exhibiting SMS features but had a normal FISH
result for 17p11.2 deletion. On analyzing their DNA sample by sequencing of the RAI1
gene, only one of them was identified with a novel RAI1 mutation. The novel mutation
identified in our patient was de novo as it was absent in the parental DNA, although the
possibility of germline mosaicism cannot be ruled out. This mutation caused a significant
nucleotide change in exon 3 that included a deletion of 4 bp starting at nucleotide 2966
(Fig. 7). This heterozygous novel deletion should result in a frameshift mutation leading
to misincorporation of 38 amino acids and truncation of the RAI1 protein. This novel de
novo mutation was consistent with the diagnosis of SMS. Previous studies in our lab and
others have identified several patients with RAI1 mutations, which along with this patient,
bring the total number of individuals with sporadic RAI1 mutations to 19 ( Fig. 9) (4, 8,
10, 15, 20, 40).
Our 17 year old patient was the first SMS case with a demonstrated RAI1 gene
mutation and absence of frank mental retardation. She showed a physical phenotype
characterized by being mildly overweight, and craniofacial and skeletal anomalies
evocative of SMS (broad face, bushy eyebrows, synophrys, upslanting palpebral fissures,
full-tipped nose, mild retrognathia, dorsolumbar scoliosis, brachydactyly of fingers and
toes, and pes planus). Other physical features were hoarse voice, dry skin, tricuspid
regurgitation, and a history of constipation and, until early infancy, hypotonia. The
clinical picture was, however, dominated by the behavioral abnormalities, which, like in
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most SMS patients, began in early childhood and increased in severity with progressing
age. The patient displayed weak relational and social skills, obsessive thinking, tendency
to depressed mood, stereotypies, significant maladaptive behaviors (temper tantrums,
disobedience, impulsivity, verbal aggressiveness, attention seeking, and prolonged
crying), self-injurious behaviors (skin-picking of the legs, onychotillomania, selfhugging, polyembolokoila-mania associated with recurrent urinary tract infections,
cutting locks of her own hair, tearing away her eyebrows, and writing and painting the
skin, mouthing of hands and objects, and grinding of the teeth), and sleep disturbances
(difficulty falling asleep, prolonged night-time awakenings, and excessive daytime
sleepiness).
The behavioral phenotype and the sleep disturbances of SMS patients can be
considered as real diagnostic ―handles‖ in the diagnosis of this syndrome. Also in our
case, these cardinal signs, along with some physical features (mainly the brachydactyly of
toes and the mild but suggestive facial dysmorphisms), were the pivotal clinical
manifestations that pointed out the possibility of the patient having SMS.
It is important to note that, although the patient showed some learning disabilities
and certain weaknesses in sequential processing and short-term memory, her IQ fell in
the low normal range, and she did not have mental retardation. In the medical literature,
no cases of SMS with IQ greater than 75 have been reported, and our patient was the first
SMS case with an absence of frank mental retardation (10).
When compared with SMS patients that have deletions, the few reported subjects
with RAI1 mutations are more likely to exhibit overeating, overweight/obese habits, dry
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Fig. 9. RAI1 variations identified in SMS patients. The schematic illustrates
mutations and polymorphisms identified in RAI1 gene. The coding exons are black and
non-coding exons are orange. All the mutations are located in exon 3 which encodes
>98% of the protein. The underlined variations were identified in the twelve patients
evaluated in present study.
Source: Slager et al. 2003; Bi et al. 2004; Bi et al. 2006; Girirajan et al. 2005;
Girirajan et al. 2006; GeneDx; Present study 2009
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skin, muscle cramping, less severe motor delay, higher functioning, and self-injurious
behaviors such as polyembolokoilamania, skin-picking and self-hugging. Moreover, they
tend to not have organ system involvement. In particular, very few RAI1 mutation
patients have been reported to have cardiac or renal anomalies. Excluding muscle
cramping, our patient showed all the clinical features typically associated with SMS due
to mutations in RAI1. However, it is interesting to note that she was the first case with an
RAI1 mutation having a cardiac anomaly of mild tricuspid regurgitation. This finding
partially enlarges the spectrum of symptomatic effects of RAI1 mutations, which is
clearly not yet completely known because of the limited number of recognized patients
and an understandable selection bias toward the more severe and typical cases of SMS.
We also identified several polymorphisms in these patients. Most of them were
known SNPs from the database, along with four novel SNPs, two of which were located
in the intronic regions (Table 4). Along with these novel SNPs, the total number of SNPs
identified in the coding sequence of the RAI1 gene is 13 (Fig. 9). Except for a few that
were in homozygous state, the majority of these SNPs were heterozygous. The intronic
SNPs that were found in SMS346 and SMS351 are located in intron 5. At present, we
are unaware of the potential cause and effect of these exonic and intronic SNPs and
hence, further studies need to be performed to evaluate their role in causing SMS
features.
Future studies to improve diagnosis of SMS
The incidence rate of this neurodevelopmental disorder is estimated to be
1:15,000-25,000 births, but it seems likely that these figures represent an underestimate
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(10). Many of these patients were initially diagnosed with some other syndrome, but
eventually when tested for 17p11.2 by FISH or RAI1 sequencing, they were identified
with deletion or mutation, and were correctly diagnosed with SMS.
For example, our patient (SMS339) was initially diagnosed with mood disorder
associated with behavioral anomalies, and the psychiatric signs were not recognized as
part of a known syndrome. It is probable that other ―psychiatric patients‖ actually have
SMS, and it is believed that this condition could easily go undiagnosed when the
cognitive impairment is lacking or the severity of mental retardation falls in the mild or
borderline range. On the other hand, both the variable expression of the clinical picture
and the still limited knowledge of the syndrome by clinicians are the principal reasons for
considering the current incidence rate figures of SMS as an underestimate. Obtaining the
correct diagnosis is of critical importance for the family and the patient, particularly so
that the patient can obtain the necessary educational, therapeutic, and medical services
needed for an individual with SMS.
Future studies are important also for those patients that are negative for deletion
of 17p11.2 region or mutation of RAI1 gene, but clearly exhibit features consistent with
SMS. Some of these cases have been evaluated for the alternative diagnosis of SMS, as
suggested by Elsea and Girirajan (2008) such as Prader-Willi, Angelman, Down, and
Fragile X syndromes (Table 8), but the laboratory findings were negative. In my study,
11/12 patients belong in this category and are classified as ―SMS-like‖ cases. There
might be several possibilities that could lead to the appearance of ‗SMS-like‘ phenotype.
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Table 8: Alternative diagnosis of Smith-Magenis syndrome.
Syndrome
9q34 deletion
syndrome

OMIM No.
#61253, *607001

Down syndrome
(Trisomy 21)

#190685, *602917,
*
605296, *605298,
*
604829

Williams
syndrome
(del(7)q11.23)

#194050, *130160,
*601329, *603432,
*
604318, *601679

Prader-Willi
syndrome
(paternal
del(15)q11-q13)

#176270, *182279,
*
602117

22q11.2 deletion
syndrome
(DiGeorge/
velocardiofacial
syndromes)
Sotos syndrome

#188400, #192430,
*
602054

Clinical Featuresa
Mental retardation, brachycephaly, flat face, midface hypoplasia,
tented upper lip, short nose, hypertelorism, synophyrys,
prognathism, hypotonia, cardiac anomalies, seizures, hearing
loss, sleep disturbance, obsessive-compulsive disorders, and
stereotypic movement
Mental retardation, hypotonia, short stature, brachycephaly,
epicanthic folds, upward slanting palpebral fissures, flat facies,
congenital heart defects, Brushfield spots (iris), single palmar
crease, brachydactyly, small and low-set ears, obtrusive sleep
apnea, and cardiac and endocrine problems
Mental retardation, characteristic ‗elfin‘ facies, supravalvular
aortic stenosis, hypercalcemia, prenatal growth retardation, short
stature, lack of depth perception, and friendly, loquacious
personality
Mental retardation, speech and motor delay, brachycephaly,
almond-shaped eyes, down-turned mouth with thin upper lip,
hypotonia, short stature, gait abnormalities, hyperphagia, genital
hypoplasia, and self-injurious and obsessive-compulsive
behaviours
Congenital heart disease, velopharyngeal insufficiency, cognitive
and motor delay, feeding difficulties, immune deficiency,
hypocalcemia, hearing loss, and skeletal abnormalities

#117550, *606681

Mental retardation, hypotonia, cognitive and motor delay,
feeding difficulties, tall stature, macrocephaly, malar flushing,
frontotemporal hair sparsity, down slanting palpebral fissures,
seizures, scoliosis, and cardiac and renal abnormalities
a
Summarized from Online Mendelian Inheritance in Man (OMIM)
Source – Elsea and Girirajan, 2008
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It is possible that RAI1 interacts with other genes or proteins via multiple
pathways that could lead to an SMS or an SMS-like phenotype. The amino acid
sequence motifs such as bipartite nuclear localization signal and PHD domain of the
RAI1 gene are found to be related to the transcription factor stromelysin-1 platelet
derived growth-factor-responsive element binding protein (TCF20) which strongly
suggests that RAI1 could be a transcription factor modulating the expression of genes
involved in a variety of cellular functions. The ‗SMS-like‘ phenotype showed by our
patients confirmed from a clinical point of view that further studies are required to fully
understand the role played by RAI1 in the biochemical and molecular pathways
important for development, cognition, and behavior and thus, improve the diagnosis of
SMS.

Conclusions
Smith-Magenis is a complex and contiguous gene syndrome affected by several
genes in 17p11.2 region. RAI1 gene is one of the 25 genes located in the SMS critical
region and mutation screening by RAI1 sequencing has proven that mutation in this gene
causes SMS. RAI1 mutations are mostly de novo as they are not present in the patient‘s
parents. Including the cohort of patients with 17p11.2 deletion and RAI1 mutations, there
exist a group of patients with familial mutations in the RAI1 gene. These familial
mutations have complicated the diagnosis of SMS, due to their clinically normal parents
and siblings. Besides the patients diagnosed with SMS, there is one more category of
patients with ‗SMS like‘ phenotype. Although these patients have SMS phenotypes, they
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are negative for 17p11.2 deletion or RAI1 mutation, which suggests a role played by a
different gene/modifier which might be upregulating or downregulating the RAI1 gene
and contributing to the phenotype. This dosage-sensitive effect of RAI1 can be evaluated
in zebrafish models by characterizing rai1 gene expression in the presence and absence
of its inducer.
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CHAPTER 3: Cloning and sequencing of zebrafish rai1 gene

Introduction - Zebrafish model
Zebrafish (Danio rerio), a tropical freshwater fish, serves as a very important
model organism in the field of scientific research. It was first used as a model organism
in the 1980‘s by George Streisinger, who induced mutations in mature germ cells of
embryos by gamma-rays and opened the arena of studying mutagenesis and gene
regulation by performing forward genetic screens in zebrafish (44). This model presents
many advantages over other model organisms such as rapid generation time, high
fecundity, external development, transparency of embryos, low cost and simpler staining
techniques for manipulation of development at all stages. Comparative genomics shows
the similarity between genomes of human and zebrafish. Humans and zebrafish have
diverged ~ 420 million years ago but have similar skeletal cell structure, including neural
crest cells (28). This makes zebrafish a useful resource in studying cranio-facial and
neurological development observed in SMS patients.

45

Broad period of embryogenesis
The seven stages of zebrafish embryogenesis are as follows: zygote (0- 0.75
hours), cleavage (0.75 – 2.25 hours), blastula (2.25 – 5.25 hours), gastrula (5.25 – 10.33
hours), segmentation (10.33 – 24 hours), pharyngula (24 – 48 hours) and hatching (48 –
72 hours) (27). The zygote stage is 1-cell stage where the chorion swells and detaches
from the newly fertilized embryo. The cytoplasm streams away from the vegetal pole
and towards the animal pole to form a blastodisc.

This defines the first stage of

embryogenesis. In the second stage known as the cleavage stage, six cleavages (2 cells to
64 cells) occur every fifteen minutes in regular orientations giving rise to 3 tiers of
blastomeres. Blastula stage is defined as the stage where the 3 tiers further divide to 11
tiers of blastomeres and the marginal blastomeres form rows of yolk synctial layer (YSL).
The YSL continues to develop and the blastula flattens and forms a sphere between the
yolk and blastodisc. This sphere begins to bulge towards the animal pole to form a
blastoderm. By the end of the blastula stage, the blastoderm covers 30% of the yolk sac.
In the gastrula stage, the blastoderm continues to cover a larger fraction of the yolk (~
90%) forming a germ-ring and then an embryonic shield. By the end of this stage, the
embryo develops 90% epiboly, brain and notochord rudiments.

The fifth stage of

development is marked by segmentation of somites (1 – 26+) which leads to the
development of primordial regions such as hindbrain-midbrain boundary, trunk, tail, and
lens. The pharyngula stage is an important stage for comparison of the morphologies of
the diverse vertebrates according to Baer‘s famous law (25). At this stage, the embryo
develops heartbeat, pigmentation, primary body organs such as brain and retina. By 48
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hpf (hours post fertilization), the differentiation of neurons and neural crest cells takes
place which further differentiates into cartilage. The yolk size starts to reduce and the
size of the head starts increasing.

The final stage of zebrafish embryogenesis, the

hatching stage is when pectoral fin buds and blades are formed, morphogenesis of the
organs is completed, and the embryo hatches. At the end of the third day or hatching
period and afterwards, they are known as ‗larvae‘ and after 90 days post-fertilization,
they are known as ‗adults‘.
rai1 gene in zebrafish
A single putative ortholog of the rai1 (XM 001333125, LOC793412) gene was
predicted in zebrafish but not fully annotated (Fig. 10). This gene is a homologous to the
RAI1 gene and conserved in human, chimpanzee, dog, mouse, rat and chicken (9). The
putative gene maps to chromosome 3 and is made up of 3 exons composed of 5824 bp
nucleotides and encodes a 1936 amino acid protein. Zebrafish putative gene sequences
based on computation analysis are added to the NCBI HomoloGene database and
Genome browser. Comparing the putative zebrafish rai1 gene sequence with available
transcripts, an expressed sequence tag (EST) (clone 2691424) was identified to have the
5‘ end of the gene along with some UTR region, approximately 500 bp (Fig. 11). As this
suggested the EST contained the full-length rai1 gene, it was bought from Open
Biosystems and sequenced with overlapping forward (F) primers (Table 9). Sequencing
the full-length clone was important because this clone was generated from a different
strain than the sequence data in the Genome Browser, and accurate sequence is required
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Fig. 10. Putative structure of zebrafish rai1 gene. LOC793412 maps to chromosome
3 of the zebrafish genome and is composed of 3 exons. This putative structure is based on
the computational analysis and projection studies performed by NCBI Homologene
database.

Fig. 11. Schematic of rai1 Expressed Sequence Tag (EST). EST was identified to
have a 5‘end and some UTR region. This suggested that it contained the full-length rai1
and was used for sequencing the 5‘end of the rai1 gene.
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to design an antisense knockdown (morpholino) and perform rescue experiments. Once
the accurate sequence of zebrafish rai1 gene is annotated, this model organism will serve
as a unique and powerful system to study dosage sensitivity of rai1 and identify new and
existing gene networks and functions.

Materials and methods
Isolation of DNA from plasmid
DNA was isolated from the plasmid containing the full-length clone
(EXELIXIS2691424) of zebrafish rai1 using DNA midi kit (Qiagen, Valencia,
California, USA).

The DNA samples were treated with RNase to eliminate

contamination by RNA. The isolated DNA was quantified by a spectrophotometer at the
absorbance ratio of 260/280.
PCR and sequencing
PCR amplification of the plasmid DNA was performed initially by using two
different combinations of the vector primers (M13F (gtaaaacgacggccagt) and M13R
(caggaaacagctatgac); T7F (taatacgactcactatagg) and M13R (caggaaacagctatgac)). Several
overlapping primers were also designed for sequencing the M13F/M13R PCR product to
obtain the remaining gene sequence that was not covered by the initial set of primers
(Table 9). PCR reaction mix and conditions were followed as described in Chapter 2
(polymerase chain reaction). Sequencing was performed at the Virginia Commonwealth
University Sequencing Core using the protocol described in Chapter 2 (Sequencing).
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Sequence analysis
The chromatograms results were received from the sequencing core and the
sequencing results from the forward primer were analyzed by comparing the results with
the predicted rai1 sequence visually by looking for variations (nucleotide change) and
sequence quality. The predicted rai1 sequence was obtained from Genome Browser and
NCBI. A poly A tail was encountered at 3720 bp (after SalI site) and sequencing results
became unclear (Fig. 12).
Table 9. Overlapping primers for sequencing rai1 gene

Forward primer

Sequence
covered

M13:
gtaaaacgacggccagt
SHE608:
gtacatgagcgaaggtcac
SHE610:
gtaaggtcgccggaacaatac
SHE614:
catggaccgagaggatg
SHE633:
atcatcacatcgattgt
SHE635:
agtccaaagccttgtccta
JL502:
caactgtggcatcagtagctaaaggc
SHE646:
gcgcccagatctaagtgacg

490 bp
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460 bp
952 bp
828 bp
656 bp
330 bp
1818 bp
897 bp

Collect cultivated embryos
Overnight tanks that separated three male from three female fish were set-up in
the afternoon. Mating took place in the morning and embryos were collected in a 10 cm
petri dish after 1-2 hours. Each petri dish contained ~ 80 embryos and the dish water was
maintained by removing empty chorions and deformed embryos.
TRIzol treatment
Collected embryos were incubated at 28.5°C until they reached the required stage.
At 72 hpf, a total of 30 embryos were homogenized in 1 ml of TRIzol reagent and stored
at -20°C until ready to isolate RNA.
RNA extraction
Total RNA was extracted from TRIzol treated (72 hpf) embryos using the RNA
preparation kit (Invitrogen), according to the manufacturer‘s instructions.
Reverse-transcriptase PCR (RT-PCR)
First strand cDNA synthesis was performed on the extracted RNA from 72 hpf
embryos according to the manufacturer‘s protocol (Stratagene Accuscript protocol) using
1 µl of 1-2 ug of total RNA, Accuscript RT buffer, Accuscript RT, oligo dT, DTT
(0.1M), Rnasin and dNTP mix (10 mM).
PCR and sequencing
cDNA obtained from RT was PCR amplified with overlapping primers (Fig. 12)
designed between the SalI site and the 3‘ end of the putative rai1 gene sequence (JL502F
(caactgtggcatcagtagctaaaggc)

and

SHE647R
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(cgtggtatgcagtcctcagg);

SHE646F

(gcgcccagatctaagtgacg) and SHE650R (tcacacacttaccttgtgtttcgg)). PCR reaction mix and
conditions were followed as described in Chapter 2 (polymerase chain reaction).
Sequencing was performed at the Virginia Commonwealth University Sequencing Core
using the protocol described in Chapter 2 (Sequencing).
Sequence analysis
The chromatograms results were received from the sequencing core, and the
sequencing results were analyzed as described in Chapter 3 (sequence analysis).
Cloning rai1 PCR products
PCR products of the correct size were purified by gel extraction using the Qiagen
Gel Extraction kit (Qiagen Inc, Valencia, California, USA). Purified PCR products (~ 10
ul) were treated with 0.25 ul of Taq polymerase (5u/ul) and 0.25 ul of dNTP (10 mM) at
72° for 10 mins.

These products were then TOPO ® cloned into pCR®2.1-TOPO®

[646/650] /pCR®4-TOPO® [502/647] vector using the TOPO® cloning kit by Invitrogen
(CA) (Fig. 13). The protocol was revised as follows: the ligation reaction was incubated
for 30 mins at 22°C, the TOPO- rai1 construct was transformed into One-Shot® - Top F‘
chemically competent E-coli cells and incubated on ice for 30 mins, and 50 ul of
transformation mix were spread on LB plate with 50 µg/ml of kanamycin and incubated
at 37°C for overnight. Colonies were grown in a culture with 5 ml of LB media and 2.5
ul of kanamycin (100 µg/ml). The culture was used to isolate DNA using the DNA miniprep kit by Fermentas (Burlington, Canada). PCR amplification of the isolated DNA was
performed by using the rai1 specific primers (JL502/SHE647; SHE646/650) to confirm
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Fig. 12. Schematic illustrating the end of EST and overlapping primers used for
obtaining 3’ end. Poly A tail was encountered at 3720 bp (cDNA ends). Overlapping
primers JL502/SHE647 and SHE646/ SHE650 were used for PCR amplification for
obtaining 3‘end of rai1 gene.

pCCM114 (A)
pCR 4-TOPO (B)
pCR 2.1-TOPO (C)

Fig. 13. Schematic representation of the three rai1 clones. The three fragments of the
zebrafish rai1 gene were present in three different vectors. (A) EST containing the 5‘end
cloned into pCCM114 vector. (B) JL502/647 fragment cloned into pCR 4 –TOPO vector
and (C) SHE646/650 fragment cloned into pCR 2.1- TOPO vector.
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the presence of the insert. DNA was also digested with restriction enzymes to check for
the insert (EcoRI) and its orientation in the vector (SacI – SHE646/650 fragment, SpeI
and BglII – JL502/SHE647 fragment). Glycerol stocks were made of the rai1 fragments
for storage purposes.

Ligation of rai1 cDNA fragments
The three rai1 fragments in three different vectors were ligated together to create
a full length rai1 clone. The SHE646/650 and JL502/647 fragments present in two
different vectors were double digested with BglII and SpeI enzymes. The digested
products were gel purified using the Qiagen Gel Extraction kit (Qiagen Inc, Valencia,
California, USA). Purified product (JL502/647) was treated with calf intestinal
phosphatase (CIP) to prevent recircularization of the cloning vector. It was further
treated with the Qiagen gel purification kit (Qiagen Inc, Valencia, California, USA).
This was followed by the ligation of the JL502/647 fragment (JL502/647 + pCR 4 vector)
and SHE646/650 (insert in pCR 2.1 vector) using T4 DNA ligase and incubating it
overnight at 14° C (Fig. 14). Once the ligation was complete, the pCR 4.TOPO- JL
502/650 rai1 construct was transformed into One-Shot® Top F‘ chemically competent Ecoli cells and incubated on ice for 10 mins, heat shocked for 40 seconds at 42°C and
incubated at 37° for 90 mins after the addition of LB. The transformations (~300 µl)
were spread on LB plates with 50 ug/ml of kanamycin and incubated at 37°C overnight.
Positive colonies were grown in a culture with 2 ml of LB media and 2.5 ul of ampicillin
(100 µg/ml). The culture was used to isolate DNA using the DNA mini-prep kit by
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Fig. 14. Ligation of two rai1 constructs at the 3’end. JL502/647 fragment (JL502/647 + pCR 4 vector) and SHE646/650
(insert in pCR 2.1 vector) were double digested with BglII and SpeI and ligated with T4 DNA ligase.

BglII

SpeI
BglII

SpeI

BglII

SpeI
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NotI
SalI

NotI

EST
SalI

NotI

SalI

Fig. 15. Ligation of 5’ end with 3’end. JL502/650 and pCCM114 containing the EST were double digested with NotI and
SalI enzymes and ligated with T4 DNA ligase.
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Fermentas (Burlington, Canada). The JL502/650 DNA was digested with NotI and SpeI
to confirm the size and orientation of the inserts. This was followed by sequencing of the
junction between JL502/647 and SHE646/650. The JL502/650 fragment was then ligated
with the 5‘end of the gene (1st fragment) in the pCCM114 vector (Fig. 15). The
JL502/650 and pCCM114 constructs were double digested with NotI and SalI enzymes.
The JL502/650 + vector (6.4 kb) was also treated with CIP to prevent recircularization.
These products were then gel purified using the gel purification Qiagen kit, followed by
the ligation of the JL502/650 construct (JL502/650 + pCR 4 vector) and 5‘ end (insert in
pCR 2.1 vector (~3720 bp)) using T4 DNA ligase and incubation overnight at 14° C (Fig.
15). Once the ligation was complete, the pCR 4.TOPO- full length rai1 construct was
transformed into E-coli cells as mentioned above. Colonies were grown in a culture with
2 ml of LB media and 2.5 ul of ampicillin. The culture was used to isolate DNA using
the DNA mini-prep kit by Fermentas (Burlington, Canada). The full length rai1 DNA
was then digested with SpeI to confirm the size of the insert. This was followed by
sequencing of the full length zebrafish rai1 gene using rai1 specific primers on the 5‘ end
(JL502/ SHE650) to confirm the junctions.

Results
Full-length rai1 gene sequence
The sequence obtained from the ligated rai1 plasmid (pCR 4 vector) had 99.5%
similarity with the putative rai1 sequence published in the NCBI database. Although
nucleotide changes were identified in our full-length rai1 clone, this could be the result of
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the different strain of fish used in our study or the putative sequence obtained from
computational study was inaccurate. This full-length rai1 sequence will serve as a
reagent for morpholino studies to eventually provide a better understanding of the rai1
gene and its role in causing cranio-facial and neurological defects.

Discussion
Analysis of rai1 in zebrafish
A full length cDNA encoding the rai1 gene from zebrafish was cloned by RTPCR of two fragments (3‘ end) and ligation of these fragments with an EST (5‘ end).
Zebrafish rai1 has an open reading frame coding for 1935 amino acids. The alignment of
the zebrafish rai1 with human RAI1 amino acid sequence shows 27 % identity (Fig. 16).
In regards to the polyglutamine region, human RAI1 is composed of fourteen glutamine
repeats. But in all other species including mouse and rat, the polyglutamine region
generally includes fewer repeats. As shown in Fig. 16, zebrafish rai1 contains two Qs in
the vicinity of the human glutamine repeat, which is consistent with the reduced number
of glutamines identified in other species. Some domains were conserved in zebrafish and
show 100% similarity (Fig. 16). The conservation of these domains serves as evidence
that the full-length rai1 clone from zebrafish in our study is truly the ortholog of human
RAI1.
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HUMAN RAI1
zebrafish rai1

10
20
30
40
50
....|....|....|....|....|....|....|....|....|....|
mqsfrercgfhgkqqnyqqtsqetsrlenyrqpsqaglscdrqrllakdy
MQSFRERSGFHSDQHCYQQEPQELPRLESYRHHYSQSRQGYEPHALASAG

HUMAN RAI1
zebrafish rai1

60
70
80
90
100
....|....|....|....|....|....|....|....|....|....|
ynpqpypsyeggagtpsgtaaavaadkyhrgskalptqqglqgrpafpgy
MSTAGSKDCYGQQNYPVYTSATQTKKPYRGGKTPNQHLQAGYSNHMGTGY

HUMAN RAI1
zebrafish rai1

110
120
130
140
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....|....|....|....|....|....|....|....|....|....|
gvqdsspypgryageeslqawgapqppppqpqplpagvakydenlmkkta
TAQYMSEGHLQQKWDESAQMTQFEQDMVGRLESGSSQYLEQNMLAISQSQ

HUMAN RAI1
zebrafish rai1

160
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180
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....|....|....|....|....|....|....|....|....|....|
vppsrqyaeqgaqvpfrthslhvqqppppqqplaypklqrqklqndiasp
CHLPAQSSAPVYTSPHQQGIPPNPAPSPLMYPQGHMHFPQHSQTSSSPSS

HUMAN RAI1
zebrafish rai1

210
220
230
240
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....|....|....|....|....|....|....|....|....|....|
lpfpqgthfpqhsqsfptsstysssvqgggqgahsyksctaptaqphdrp
AYMDKCNTASHGYKGYGIPPNAQYGRQLSNHSSLKQSGYRPQNNYGYQQT

HUMAN RAI1
zebrafish rai1

260
270
280
290
300
....|....|....|....|....|....|....|....|....|....|
ltassslapgqrvqnlhayqsgrlsydqqqqqqqqqqqqqqalqsrhhaq
PSRSGFEQGSLQGMSGTQESLQKFQYYNQTQQNYCITDISVRSPEQYYQT

HUMAN RAI1
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310
320
330
340
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....|....|....|....|....|....|....|....|....|....|
etlhyqnlakyqhygqqgqgycqpdaavrtpeqyyqtfspssshsparsv
CSPSSSHSPARSVGRSPSYNSTPSPLMANADSFQYGQPPINPGASSSTGL
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380
390
400
....|....|....|....|....|....|....|....|....|....|
grspsysstpsplmpnlenfpysqqplstgafpagitdhshfmpllnpsp
QNEQNMLMPPHTHSSSSVNQTQSFSGSMKERFSEKLLTNPSLWSLNALTS
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HUMAN RAI1
zebrafish rai1

420

430

440

450

....|....|....|....|....|....|....|....|....|....|
tdatssvdtqagnckplqkdklpenllsdlslqsltaltsqvenisntvq
QVENISNNVQQLLLSEALMASKKTSKRNHPKKGEDYRGQLEGMDESCPEN
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HUMAN RAI1
zebrafish rai1

460
470
480
490
500
....|....|....|....|....|....|....|....|....|....|
qlllskaavpqkkgvknlvsrtpeqhksqhcspegsgysaepagtplsep
QHGPSPSDAYSIPRSMTAGLQEGGYSSSTEDQMERNYYYFGQEKGQGHTQ
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510
520
530
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....|....|....|....|....|....|....|....|....|....|
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THSRLSLDTVSTCSLNSADDVSVRSGDSVRSLQSVASEDNLNCDPRVQRA
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560
570
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....|....|....|....|....|....|....|....|....|....|
esvstcsvtspddmstksddsfqslhgslpldsfskfvagerdcprllls
LSEEEPDSSLCCIRDERSPIGVTAPSPMKQESDSPPDIKRSESTQKENFE
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620
630
640
650
....|....|....|....|....|....|....|....|....|....|
alaqedlaseilglqeaigekadkawaeapslvkdsskppfslenhsacl
ESAWTERMADEDKTEQSKPSAEHDCKGEVTEKQEKWLEDEKGPALFQKIN

HUMAN RAI1
zebrafish rai1

660
670
680
690
700
....|....|....|....|....|....|....|....|....|....|
dsvaksawprpgepealpdslqldkggnakdfspglfedpsvafatpdpk
KTVLEEGYSYETEENIYQGLQNKYDSEKENTTEIDCFAELNHKCDEDTEI

HUMAN RAI1
zebrafish rai1

710
720
730
740
750
....|....|....|....|....|....|....|....|....|....|
kttgplsfgtkptlgvpapdpttaafdcfpdttaassadsanpfawpeen
KTEHFKSEPQTSVEMPTEDSPSNSATELCLPEKEEHSSSENSVETPTCTL

HUMAN RAI1
zebrafish rai1

760
770
780
790
800
....|....|....|....|....|....|....|....|....|....|
lgdacprwglhpgeltkgleqggkasdgiskgdtheasaclgfqeedppg
EGPADTLEEQTSVLSHTSTEVGDEKDSILTSSEEVINNKTESQESFPDVC

HUMAN RAI1
zebrafish rai1

810
820
830
840
850
....|....|....|....|....|....|....|....|....|....|
ekvaslpgdfkqeevggvkeeaggllqcpevakadrwledsrhccstadf
GTYEEAENMQQVNTETAESIAQDTPHRDSERRSVICDIAPQTHTAKSDFS

HUMAN RAI1
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860
870
880
890
900
....|....|....|....|....|....|....|....|....|....|
gdlpllpptsrkedleaeeeysslcellgspeqrpgmqdplspkaplict
ALNEKTTPLAQARDHHIDCSDAKVLEPDSPQLPGKSILHSAPSWADTPPS
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HUMAN RAI1
zebrafish rai1

910
920
930
940
950
....|....|....|....|....|....|....|....|....|....|
keeveevldskagwgspchlsgesvillgptvgteskvqswfesslshmk
PKKADEDMEPGINCPSAVTPSAKPEAFTPSSHTRMFGKKHVRGRRRPMSS
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RAIKNNHEMHLKQRKKRRKGTEPQENIPIVEQPESTQTEVLPTSPPPPET

HUMAN RAI1
zebrafish rai1

1560
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....|....|....|....|....|....|....|....|....|....|
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LEQTECKEPPNEVCVPLMKPKRGRRPSLKKKQEELSKSQKEDENAIEKKK
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....|....|....|....|....|....|....|....|....|....|
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....|....|....|....|....|....|....|....|....|....|
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YVHIDSSMDVASSCTIVNRPEEEQMLAQARTKSVPNIKNQAAKTGSNSSV
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1730
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dlcgpyypehclpkkkpklkekvrpegtceeaslplertlkgpecaaaat
MLQGPLVNKSLSDRCLTCCLCGKPANYRELGDLCGPYYPEDCIPRKTLSL
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Fig. 16. Alignment of human and zebrafish RAI1/rai1 amino acids. Like
human RAI1, zebrafish rai1 contains nuclear localization signals, a PHD domain,
and poly serine domains, and shows similarity to TCF20. Zebrafish rai1 is
composed of many amino-acid domains that are conserved in human and share
100% similarity. These amino-acids sequences can be acting as regulatory factor
for normal RAI1 functioning and their conserved nature helps in aligning the
protein. The conservation of the domains between human and zebrafish strongly
suggest that this clone is an ortholog of human RAI1.
List of Domains (% identity to human)
Similarity to TCF20 – MQSFRER (100%)
Glutamine region – QQ (Human RAI1 typically carries 13 Q‘s, while mouse carries 4)
Nuclear localization signal (3) - KKRKKGRQDEVKAQDSPLDIVHIPKGKRK
KKRRK
KKKQEELSKSQKEDENAIEKKK
Polyserine domain – SPSSSHSPARSVGRSPSYNSTPSPLM (100%)
PHD domain – KCSGCQGEGASVCCGWKSCTQSYHYICAKESGCTFEEETFSIRCPKHK (24%)
Conserved domain - HFPQHSQ (100%)
Conserved domain - PEQYYQT (100%)
Conserved domain –ALTSQVENIS (100%)
Conserved domain – VQQLLLS (100%)
Conserved domain – VSTCS (100%)
Conserved domain – LCGPYYPE (100%)
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CHAPTER 4: Spatial and temporal rai1 expression in zebrafish

embryos

Introduction
In order to understand the dosage-sensitive role of rai1 gene and its effect on
complex phenotypes, it is important to evaluate the zebrafish model that is
overexpressing or deficient in rai1 and compare the result with wild-type zebrafish with
normal levels of rai1. In humans, RAI1 mRNA is generally expressed in all tissues but
present at high levels in heart and neuronal structures (40, 46). Similarly in mouse,
immunohistochemistry (IHC) with a Rai1 antibody detected expression mainly in
cerebral cortex, cerebral hemisphere, ganglion, thymus, and midbrain (Fig. 17).
Preliminary data from zebrafish studies show rai1 expression in the lens, midbrain, and
diencephalon. A complete spatial and temporal profile of rai1expression will facilitate
the background for evaluating the changes in gene expression and morphology in the
presence of altered levels of rai1.

64

Midbrain

Cerebral cortex

Cerebral
hemisphere

Ganglion

Thymus

18 dpc
IHC with Rai1 ab

72 hpf
ISH with rai1 probe

Fig. 17. rai1 expression in mouse vs. zebrafish. As in mouse, zebrafish show
widespread rai1 expression during embryonic development. Expression in both species
becomes more specific in certain areas, especially in the brain. The expression in mouse
is detected in the cerebral cortex, ganglion, thymus, and midbrain (Girirajan Dissertation,
2008). The expression in zebrafish is detected in similar regions including midbrain,
forebrain and diencephalon.
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Materials and methods
Zebrafish culture and maintenance
Zebrafish lines
Wild-type adult fish of AB strain were used for the experiments.
Aquarium system
Zebrafish were maintained in recirculating system water with the 500 µS as the
parameter of conductivity, 27-28°C as the temperature, optimum chemical and biological
pressure, UV sterilization, and pH of 7. For breeding, approximately 8 adult fish were
placed in 3.0 liter tanks.

Early stages - (<2.5 hpf, 9 hpf, 15hpf and 18hpf)
Collect cultivated embryos
Embryos were harvested and collected as described in Chapter 3.
TRizol treatment
Collected embryos were incubated at 28.5°C until they reached the required stage.
At the various stages such as <2.5 hpf, 9 hpf, 15 hpf and 18 hpf, a total of 30 embryos
were homogenized in 1 ml of TRizol reagent and stored at -20°C until ready to isolate
RNA.
RNA extraction
Total RNA was extracted from the trizol treated embryos using the RNA
preparation kit (Invitrogen), according to the manufacturer‘s instructions.
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Reverse-transcriptase PCR (RT-PCR)
First strand cDNA synthesis was performed as described in Chapter 3.
Semi-quantitative PCR
cDNA obtained from <2.5, 9, 15 and 18 hpf embryos was PCR amplified with
internal control (TCOF1- like gene) primers [F (gcgatctctaccaacatgtg) and R
(cttggctgatgggccattga)]. rai1 was then PCR amplified with primers in the exon 3 region
[rai1F (agggcactgtctgaagagga) and rai1R (ttggcagtgtgagtctgagg)], followed by PCR
amplification using primers spanning the exonic boundary of rai1 exon 2 and 3 [SHE646
(gcgcccagatctaagtgacg) and SHE650 (tcacacacttaccttgtgtttcgg). PCR reaction mix and
conditions were followed as described in Chapter 2 (Polymerase chain reaction). PCR
products were evaluated by gel electrophoresis.

Later stages - (24, 30, 31, 35, 37, 48 and 72 hpf)
Collect cultivated embryos
Embryos were harvested as described in Chapter 3. There were a few exceptions
to the previous protocol, including the addition of 2 µl of methylene blue for fungus
prevention and 500 µl of 0.12% of 1-phenyl-2-thiourea (PTU) to inhibit pigmentation, in
each petri dish with ~ 80 embryos and then incubated at 28.5°C.
Probe preparation
A glycerol stock of the plasmid containing the 5‘ end (exon 1) of zebrafish rai1
gene (Fig. 18) was used to grow colonies for DNA isolation. DNA was extracted using
the mini kit by Qiagen (Valencia, California, USA), according to the manufacturer‘s
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protocol. The isolated DNA was quantified by a spectrophotometer. The DNA template
was linearized by digesting 5 µg, overnight at 37° C with BamHI enzyme (anti-sense
probe) and with NotI enzyme (sense probe). After the enzyme digest, the DNA/probe
was purified from the solution using the ultraclean kit by Molecular Biology labs
(Carlsbad, CA). DNA was then quantified by a spectrophotometer. This was followed
by a transcription reaction containing 8 µl of nuclease-free water, 4 µl of transcription
buffer (5X), 2 µl of DIG-NTP mix (10X), 1 µl of RNA polymerase (T7 - antisense probe
and SP6 – sense probe), 1 µl of RNasin and 1 µg of linearized DNA templates, all
assembled in order and incubated at 37°C (antisense probe) and 40°C (sense probe) for 2
hours. This was followed by the addition of 1 µl of RNase-free DNase I after the
transcription reaction and incubation at 37°C for 15 mins. Finally, the digoxigeninlabeled probe was purified by using Probe Quant G-50 micro column purification kit by
IllustraTM (Buckinghamshire, UK) and 80 µl of hybridization buffer [50% formamide, 5X
sodium citrate buffer (SSC), 50 µg/ml heparin, 0.5 mg/ml yeast tRNA, 0.1% tween-20,
9.2 mM of citric acid, and nuclease-free water] was added to the purified probe and
stored at -20°C. The probe sequence was aligned with the putative rai1 gene and it was
found to be identical to the 5‘ end (beginning of exon 1) of the rai1 gene (Fig. 18 and
19).
In-situ hybridization
As mentioned earlier, embryos were incubated at 28.5°C until they reach the
required stage. At these stages, ~ 30 embryos were dechorionated and anesthetized by
addition of 20 µl of MESAB before they were fixed in 4% of paraformaldehyde (PFA)
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for overnight on the shaker. Next day, PFA solution was replaced with methanol and the
embryos were stored at -20°C for overnight. The embryos were then rehydrated through
methanol/PBT series washes (100%: 0%, 66%: 33%, 33%: 66% and 0% : 100%) for 5
mins on the shaker. These washes were followed with Proteinase K (PK) treatment: 1 µl
of PK in 1 ml of PBT for 2.4 mins for 24 hpf embryos and 4.8 mins for 48 hpf embryos
and so on. This was followed by aspiration of PK solution and post-fixation of the
embryos with 4% PFA on the shaker for 20 mins. After post-fixation, the embryos were
washed several times with PBT and then incubated in Hyb (+) for > 1 hour in water bath
set at 65°C. The solution was replaced with diluted probe (1:200) in Hyb (+) and
incubated overnight at 65°C. Next day, the diluted probe solution was aspirated and
saved for re-use. It was replaced by (Hyb -) buffer [hybridization buffer without tRNA
and heparin] for a quick wash followed by series of Hyb (-)/ 2 X SSC series (66% :33%,
33%: 66%, 0%: 100%) for 10 mins at 65°C, and two 20 mins washes of 0.2 X SSC at
65°C. This was followed by three serial washes of 0.2XSSC/PBT (66%: 33%, 33%:66%,
0%:100%) for 5 mins on the shaker. Embryos were then treated with blocking solution
[1X PBT, 2 mg/ml bovine serum albumen (BSA), and 2% goat serum (GS)] for 1 hour on the
shaker. This blocking solution was replaced with alkaline-phosphatase-coupled antidigoxigenin FAB fragments diluted (1:10,000) in blocking solution and incubated overnight
at 4°C. On day 5, embryos were washed five times with PBT for 15 mins on the shaker.
This was followed with three washes of coloration buffer [0.1 M Tris hydrochloride (pH 9.5),
50 mM MgCl2, 0.1 M NaCl and dH20] with 0.1% Tween 20 for 5 mins on the shaker. After
these washes, the solution was replaced with nitro blue tetrazolium [NBT] [225 μg/ml] and
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bromo-4-chloro-3-indolyl phosphate [BCIP] added in coloration buffer with Tween, and the
embryos were kept in the dark box on the shaker during the day and incubated at 4°C during
the night for two consecutive days. When the embryos were stained sufficiently, the
coloration buffer was aspirated and the embryos were given a quick PBT wash. The embryos
were then dehydrated with methanol for ~ 20 mins on the shaker to clear out the background.
Before performing the imaging, the embryos were rehydrated through a methanol/PBT series
and equilibrated in 1X PBS with 50% glycerol. All pictures were taken with an Olympus
SZX12 microscope and Olympus DP70 camera using an 80X objective lens.
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Fig. 18. Schematic representation of the ISH probe. Probe maps to the 5‘end of the
exon 1 region of the putative rai1 gene.
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SP6
putative rai1
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....|....|....|....|....|....|....|....|....|....|
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--------------------------------cctatctggagtc----a
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tgcagtccttcagagagcggagtggtttccatagcaaccagcactgctac
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putative rai1
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....|....|....|....|....|....|....|....|....|....|
cagcaggaaccccaagaattaccgcgcctcgagagctacagacatcatta
cagcaggaaccccaagaattaccgcgcctcgagagctacagacatcatta
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....|....|....|....|....|....|....|....|....|....|
cagccagtccagacagggctacgagccacacgctttagcttctgccggga
cagccagtccagacagggctacgagccacacgctttagcttctgccggga
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260
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....|....|....|....|....|....|....|....|....|....|
tgtcaacagcgggatctaaagactgttacggacagcagaactatcctgtc
tgtcaacagcgggatctaaagactgttacggacagcagaactatcctgtc
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tacaccagcgccacacagactaagaaaccatacagaggaggcaaaactcc
tacaccagcgccacacagactaagaaaccatacagaggaggcaaaactcc
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gctcagatgacccagttcgagcaggacatggtgggtcgtctggagtctgg

Fig. 19. Alignment of the ISH probe with the rai1 gene sequence. The anti-sense
probe was sequenced with the SP6 primer. This sequence when aligned with the putative
rai1 gene, is identical to the 5‘ end (beginning of transcription in exon 1-- ATG) of the
rai1 gene.
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Results
rai1 expression detected at early stages
Gel electrophoresis results from rai1 RT-PCR from <2.5 hpf, 9 hpf, 15 hpf, and
18 hpf zebrafish embryos is shown in Fig. 19. Internal control (TCOF1- like gene)
spanning the exonic region showed expression at all stages verifying the good quality of
the cDNA. RT-PCR analysis detected rai1 gene expression during early zebrafish
embryogenesis at 9, 15 and 18 hpf. A maternal rai1 transcript (< 2.5 hpf) was not
detectable/present in early embryonic development.

Fig. 20. RT-PCR showing rai1 expression at early stages. Internal control (TCOF1like gene) shows expression at all stages (yellow). rai1 expression is detected at 9 hpf, 15
hpf and 18 hpf but not at < 2.5 hpf, using specific primers spanning rai1 exonic region
(blue).
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rai1 expression patterns at later stages

The rai1 expression patterns observed in zebrafish embryos was similar to the
known Rai1expression patterns seen in mouse at corresponding developmental stages
(Fig. 17). As in mouse, zebrafish embryos showed widespread rai1 expression during
embryonic development, especially in the brain and neuronal areas as shown by ISH.
The spatial and temporal profile of zebrafish rai1 expression is shown in Fig. 21. At 2430 hpf, rai1 expression was detected everywhere in the embryos, particularly in the
forebrain and diencephalon. As the developmental stage progressed, the expression
became more specific in the forebrain, midbrain and diencephalon. The rai1 expression
observed in the lens of the embryos was an artifact as indicated by the similar expression
detected in the control embryos.
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Fig. 21. Spatial and temporal profile of rai1 expression. (a,c) rai1 expression was detected throughout the embryo at 24-30
hpf. Expression became more specific to the brain regions including midbrain, forebrain, and diencephalon from 31 hpf
onwards and was observed in the brain through 72 hpf. (b,d) No expression detected in control embryos. Expression in the lens
was an artifact, as similar expression was also detected in the control embryo.
(Anti-sense)

Midbrain

Forebrain

Diencephalon

(a)
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30 hpf

31 hpf

(b)

Control
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(c)
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(d)
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72 hpf

Discussion
Spatial and temporal profile of rai1 expression
rai1 expression was detected by reverse transcriptase polymerase chain reaction
(RT-PCR) and whole-mount in-situ hybridization (ISH) in developing zebrafish embryos
in tissue-dependent and time-dependent fashion. RT-PCR detected rai1 expression at 9
hpf, 15 hpf and 18 hpf (Fig. 20). Maternal expression (< 2.5 hpf) was not
detected/present in early embryonic development. ISH detected rai1 expression in
zebrafish embryos at different developmental stages (24-72 hpf). Although the
expression was present throughout the embryo at 24 hpf; it became more restricted with
the progressing developmental stage (~ 35 hpf). The expression was specific in neural
tube and brain regions such as diencephalon, midbrain and forebrain as shown in the Fig.
21. But the expression became localized specifically to the brain regions in later stages
(~ 48 hpf). The expression observed in the lens was an artifact as seen by similar
expression in the control embryos. The completed spatial and temporal profile of normal
rai1 expression established the background necessary to monitor changes in morphology
and gene expression associated with rai1 response to RA treatment.
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CHAPTER 5: rai1 expression in response to retinoic acid

Introduction
Previous studies have shown RAI1 as the primary gene underlying the SMS
phenotype, and its haploinsufficiency causes SMS (10). Patients with SMS exhibit
craniofacial abnormalities, behavioral abnormalities, sleep problems, developmental
delay and other manifestations. This suggests that RAI1 gene dosage is critical for
normal growth, development and behavior. Hence, it was important to investigate the
factors playing a role in regulating RAI1 gene dosage and expression.
Retinoic acid
In 1995, Imai et al had shown the upregulation of the Rai1 gene in mouse P19
cells in response to the induction by RA and RA had led to differentiation of the neurons
(26). This suggested an indirect role played by RA in causing SMS phenotype. In
addition to this, many other studies (14, 25) have shown the dosage effects of exogenous
RA resulting in craniofacial anomalies in both mouse (28) and zebrafish embryos (9) and
human. To further investigate the effects of RA concentrations on rai1 expression and
zebrafish development, zebrafish embryos were treated with varying concentrations of
RA, and the rai1 expression and morphology was compared to the wild-type embryos
with normal rai1 expression.
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4-Diethylaminobenzaldehyde
Diethyaminobenzaldehyde (DEAB) is an inhibitor of retinaldehyde
dehydrogenases 2 (41, 42) and prevents the production of RA. Assessing the rai1
expression in the absence of RA helped in determining the overall impact of RA on rai1
gene expression.

Materials and methods
Preparation of RA and DEAB
All-trans RA was obtained in powder form (Sigma) and RA stocks were made in
ethanol at 200 µM concentration. The stock was diluted to 4 µM/ 20 uM in DMSO and
then 10 µl of this working stock (4 µM /20 µM/) + 10 µl of DMSO was added to 20 ml of
embryo medium to make the final concentration of RA to 2 nM/10 nM. Similarly,
DEAB (Sigma) stocks were made in ethanol at 100 mM concentration and diluted to 10
mM in DMSO. Then, 10 µl of this working stock (10 mM) + 10 µl of DMSO was added
to 20 ml of embryo medium to make the final concentration of DEAB at 5µM. For the
combined treatment of RA + DEAB, 10 µl of RA (4 µM/20 µM) + 10 µl of DEAB (10
mM) was added to 20 ml of embryo medium. Compounds were added at various
timepoints to determine the critical period of responsiveness.
Collect cultivated embryos
Embryos were harvested and collected as described in Chapter 3. There were a
few exceptions to the previous protocol, including the addition of RA (2 nM/10 nM)
only, DEAB (5 µM) only , RA (2 nM /10 nM) + DEAB (5 uM) and DMSO (control) in
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20 ml of embryos medium (1X) instead of water in each petri dish with ~ 80 embryos.
This was followed by 2 µl of methylene blue to prevent fungus growth and 500 µl of
0.12% of 1-phenyl-2-thiourea (PTU) to inhibit pigmentation, in each petri dish and then
incubated at 28.5°C.
Experimental set-ups
Three different experimental set-ups were arranged to investigate the effect of
half-life of RA and DEAB on the developing embryos. Eight petri dishes were set-up
with ~ 80 embryos in each of them, and four of them contained embryo medium with RA
(only)/DEAB (only)/RA+DEAB (both) and DMSO (control) along with methylene and
PTU. In the first set-up, embryos were treated with RA and DEAB only once at 8 hpf.
The second experimental set-up contained embryos treated with higher concentration of
RA at 10 nM instead of RA at 2 nM on first day (8 hpf), while the third set-up had two
different set of groups. The first group of embryos were treated once at 8 hpf while the
other group of embryos has the treatment changed on first (8 hpf) as well as second day
(27 hpf).
In-situ hybridization
Refer to the protocol described in Chapter 4.
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Fig 22. Experimental set-ups to investigate the effect of RA and DEAB on embryos.
Embryos were treated with RA/DEAB/RA+DEAB treatment at different time points.

Results
Effect of RA on rai1 expression
Treatment of zebrafish embryos at 24 hpf with 2 nM RA expanded expression of
rai1 throughout the nervous system (Fig. 23). Treatment of 48 hpf embryos with the
same concentration of RA (2 nM) induced expression similar to previous stages, but was
more specific to the forebrain, midbrain, and diencephalon. Treatment at the same stage
(48 hpf) as well as 30 hpf and 72 hpf, with 5-fold higher concentration of RA (10 nM)
demonstrated the variable response of the rai1 expression (Fig. 24). For example, the
expression was much higher in specific regions including diencephalon, midbrain, and
forebrain. Similar results were observed in embryos treated twice with RA (2 nM/10
nM) at different timepoints (Fig. 25). Hence, in the presence of exogenous RA, rai1
expression is induced in a non-specific manner throughout the embryo at 24 hpf but
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becomes higher and specific by 48 hpf. Hence, rai1 is regulated by RA in a tissue and
time specific manner.

Effect of DEAB on rai1 expression
Compared to untreated zebrafish embryo (DMSO), DEAB (5 µM) treated
embryos at 24 hpf, 30 hpf , 48 hpf and 72 hpf had a significant reduction of the rai1
expression in the trunk (spinal cord), but the expression remained high in brain regions
(Fig. 23 and 24). Similar results were observed in embryos treated twice with DEAB at
different time points (Fig 25). These embryos were deformed with shortened hindbrains,
slightly rounded somites, shortened and curved body axes, inflated yolk sac and mild
cardiac edema.

RA + DEAB counteract each other
The zebrafish embryos were also treated with the combination of RA (2 nM/ 10
nM) + DEAB (5 µM). The rai1 expression in these embryos at 24 hpf, 30 hpf, 48 hpf and
72 hpf was similar to rai1 expression observed in the DMSO treated (control) embryos
(Fig. 23 and 24). Similar results were observed in embryos treated twice with RA +
DEAB at different timepoints (Fig. 25).
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Fig. 23. Effect of RA (2 nM) and DEAB (5 µM) on zebrafish embryos. RA induces rai1 expression throughout the
embryos at 24 hpf and becomes specific to the brain regions by 48 hpf. DEAB reduces expression in the neural tube
but it remains high in the brain regions. RA + DEAB counteracts each other and expression is similar to DMSO.

24 hpf

48 hpf
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Fig. 24. Effect of RA (10 nM) and DEAB (5 µM) on zebrafish embryos. rai1 expression is similar to Fig. 23.
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Fig. 25. Effect of RA (10 nM) and DEAB (5 µM) on zebrafish embryos. rai1 expression is similar to Fig. 23.
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Discussion
RA is not solely responsible in inducing rai1 expression
Expression of rai1 in response to the presence or absence of retinoic acid at two
different concentrations was assessed in the developing zebrafish embryos (Fig. 23 and
Fig. 24). Retinoic acid (RA) is a derivative of vitamin A and has been shown to induce
the upregulation of the rai1 gene in cultured cells. On the other hand, diethylaminobenzaldehyde (DEAB) is an inhibitor of retinaldehyde dehydrogenases and stops the
production of RA. Deprivation of RA leads to craniofacial anomalies as shown in
previous studies (9, 14, 25, 28). In our study, DMSO treated embryos served as the
control for normal rai1 expression. ISH results from 24 hpf and 48 hpf indicated that RA
treatment at 2 nM concentration induced rai1 expression throughout the embryo as
compared to the DMSO treated embryos (Fig. 23). Similar results were also observed in
embryo at 30 hpf, 48 hpf and 72 hpf stages when treated with higher concentration of RA
(10 nM) (Fig. 24). DEAB treatment at 5 µM concentration reduced the rai1 expression
in the trunk (spinal cord) but the expression remained high in the brain region (Fig. 23
and 24). However, these embryos were greatly deformed with shortened hindbrains and
faces, slightly rounded somites, shortened and curved body axes, inflated yolk sac and
also displayed mild cardiac edema and were difficult to study. The combination of RA
and DEAB treatments counteracted each other, and the rai1 expression was similar to the
DMSO treated embryos. Similar results were observed in embryos treated twice with
RA/DEAB or RA + DEAB at different timepoints (Fig 25). Due to the fact that DEAB
treatment inhibited RA but did not take away the rai1 expression throughout the embryo,
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it suggests that RA is not solely responsible for rai1 expression at the developmental
stages studied by ISH. Further studies assessing rai1 expression at the cellular level
should be performed to investigate if rai1 expression in response to RA is cell-type
specific.
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CHAPTER 6: Discussion

RAI1/rai1 gene dosage effects in humans and zebrafish
Genetic syndromes such as Prader-Willi, Williams, Down, and Fragile X are
complex disorders involving dysregulation of several developmental process that
maintain normal growth and behavior. Smith-Magenis syndrome is a complex
neurobehavioral disorder caused by a 17p11.2 deletion or a mutation in the RAI1 gene.
Cases with 17p11.2 deletions always have a deletion of RAI1 gene. However, the
mutation cases have a single base change or microdeletion in the RAI1 gene that causes
SMS. Phenotypic comparison between the 17p11.2 deletion and mutation cases indicates
that haploinsufficiency of the RAI1 gene is responsible for causing SMS features (15).
Previous studies in mouse P19 cells have shown that RA induces the Rai1 gene (26).
Taken together, these data suggest that RAI1 gene dosage is vital for normal development
and behavior. Zebrafish is an excellent model system to study dosage-sensitivity of the
rai1 gene. Using zebrafish as a model, we cloned zebrafish rai1 gene, evaluated the
spatial and temporal profile of rai1 expression and investigated the role of RA on rai1
expression. Results from this study show the rai1 gene was expressed in a timedependent and tissue-dependent manner and RA was not solely responsible for inducing
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rai1 gene expression. It seems like there are several factors/pathways regulating the
expression and function of rai1 gene. Future experiments exploring the factors
regulating the rai1 gene and the required rai1 dosage threshold for normal growth,
development and behavior are necessary to increase our understanding of this gene. The
results from these studies will facilitate insight about treatment options that can alleviate
some of the phenotypic SMS features and prevent the morbidity associated with this
syndrome.
Future studies
Future research on SMS and the rai1 gene using the zebrafish model could include
creating a rai1 antisense morpholino to perform knockdown, or overexpression studies.
This will be achieved if the cells are prevented from making rai1 protein or make the
protein in excess. If this knockdown or overexpression causes developmental problems,
we can learn about the function of rai1 protein and its role in the developmental process.
We can use the rai1 full length clone to perform rescue experiments to show that the
phenotype of any knockdown is specific to rai1. This will determine the contribution of
the rai1 gene to any phenotypic features observed with knockdown of rai1 in zebrafish.
Additionally, we can investigate upstream and downstream effects of rai1 RNAi
knockdown on other candidate genes. Microarray analysis data obtained from RAI1RNAi knockdown cell lines and cells overexpressing RAI1 revealed a defined group of
genes that had their expression increased or decreased in response to RAI1 suppression
(Girirajan et al., 2008). First, we need to determine if these genes are present in the
zebrafish genome and then evaluate how these genes are regulated in the absence or
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presence of rai1 in zebrafish. In short, the zebrafish model is an ideal system for
investigating pertinent questions regarding the molecular and biochemical pathology of
SMS and RAI1 gene.
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APPENDIX A

Refined protocol for RAI1 mutation screening

1. Run PCRs with RAI1 specific primers. (Refer to Table 1)
PCR Reaction Mix:









2.5 μl 10x PCR buffer
0.5 μl 10 mM dNTPs
0.5 μl 20 μM forward primer
0.5 μl 20 μM reverse primer
0.25 μl Taq (5U/μl)
4 μl BSA (1 mg/ml) – {except SHE345/664}
15.75 μl dH2O
1.0 μl genomic DNA (~ 50 ng/μl)  DNA must be added at the END

Total Volume: 25 μl (per reaction)
Cycling Conditions:
94 °C

5 min

94 °C
Ta

1 min
1 min
1 min (~ 1 Kb product)
2 min (~ 2 Kb product)

72 °C
72 °C
4 °C

35 cycles (Ta – Refer to Table 1)

10 min
indefinite

2. Gel Electrophoresis
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Make a 1% agarose gel.
o Weigh out 0.30 g agarose.
o Combine agarose and 30 mL TBE Buffer in an Erlenmeyer flask.
o Heat mixture in the microwave in 10 sec increments to completely
dissolve the agarose.
o Cool solution by running flask under cold tap water.
o Add 3 μL ethidium bromide to the flask. Swirl to mix.
o Pour agarose solution into gel molds. Let gel set; ~ 15 minutes.
Run Products
o Fill electrophoresis chamber with TBE Buffer and place gel in
center.
o Add 3 μL of DNA Ladder (Hyperladder II) to well on far left.
o On a piece of parafilm place 1 μL drops of 5x loading dye. 1 drop
for each PCR product.
o Add 4 μL of PCR product to one drop of dye and mix with pipet.
Load sample in gel.
o Run gel at 100 V for 30 minutes.
o Examine gel under UV lamp (11th floor, Sanger Hall) and take a
picture.
o If a single clear band is present with the correct length follow-up
with Step 3: Clean PCR Products.
o If multiple bands are present perform a gel extraction using the
Qiagen Gel Extraction Kit and Protocol. Send purified product
directly for sequencing—these products do not need treatment with
ExoSAP-IT.

3. Clean PCR Products




Use a 96-well PCR plate for several reactions. Otherwise, use individual
PCR tubes.
Mix 5 μl PCR product with 2 μl ExoSAP-IT (USB 78200) for a combined
7 μl reaction volume.
Place in thermocycler under these conditions:

SAP (PCR Machine – User: Santhosh)
37 °C
30 min
80 °C
15 min
To inactivate ExoSAP-IT
4 °C
indefinite


The PCR product is now ready for use in DNA sequencing. Treated PCR
product may be stored at -20 °C until required.

4. Send Treated PCR Products to Massey Core Lab for Sequencing
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Use either 1.5 ml individual microcentrifuge tubes or 96-well plate for
samples.
Tube 1: Add 3 μl dH2O to 7 μl of treated PCR product for a total volume
of 10 μl to be sent for sequencing.
Tube 2: Add 10 μl diluted primer: 8 μl dH2O + 2 μl of 20 μM primer
(Refer to page 3 for details regarding use of forward and reverse primers)

5. Analyze Sequence Data




Analyze by comparing patient sequencing results with the normal RAI1
gene sequence. Look at sequence quality and for heterozygosity.
Blast using ClustalX/Bioedit
Provide sequencing data with a summary sheet of results for each
amplimer and sequencing primer to Dr. Elsea

6. Documentation of Data





Draft a Report. (Windows in Lab Office – click on Documents to Elsea
lab 2009 to Sequencing Reports, and then use the most updated one as a
template, 2008)
Update Database on Mac (Mutation Summary)
Mail report to referring geneticist once Dr. Elsea signs and approves final
report.
Attach a copy of report along with the sequences to the patient SMS file
and file it in the cabinet.

Sequencing Plan for PCR Products
1st Round of Sequencing
Process the following PCR amplicons with the suggested forward (F) and reverse (R)
primers






SHE323/508
o Primers – SHE666 (R), SHE506 (R), SHE507 (F)
SHE327/330
o Primers – SHE328 (R), SHE329 (F)
SHE329/332
o Primers – SHE331 (F)
SHE513/514
o Primers – SHE514 (R)
SHE515/516
o Primers – SHE515 (F)
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SHE335/669
o Primers – SHE336 (R), SHE669 (R)
SHE527/528
o Primers – SHE527 (F)
RA46/45
o Primers – RA46 (F)
SHE345/664
o Primers – SHE664 (R)

**If the 1st round of sequencing does NOT cover the entire region, then follow-up
with the 2nd round of sequencing.

*You may need to repeat a sequence if the sequence is not clear and readable.
2nd Round of Sequencing
Send the following PCR products with highlighted primers only
 SHE505/506
 SHE507/508
 SHE325/326
 SHE509/510
 SHE511/512
TABLE 1. RAI1 PRIMERS
Exon
Start E 3
E3
E3
E3
E3
End E 3
E4
E5
E6

Product
Size

Primers
SHE323: TCTGAGGCAAAAGGAAGTGG
SHE508: CATGTCGTCAGGAGAGGTCA
SHE327: TGTCAAGAACCTCGTGTCCA
SHE330: AACCAGCTCTGGACCTTTGA
SHE329: TCTCGCTGGAGAACCACAG
SHE332: ATGAAGGCCGACTTCCTTTT
SHE513: GCTCCAAGACCAAGGAGACA
SHE514: GCCTCGGTTTTGAAACAGTCA
SHE515: GGCCTCTCCTGGTAATCCTC
SHE516: GCAGCAAACAAGGCAAGAGGT
SHE335:AAACCGAGGCCTTCACATC
SHE669: GTGTGACCTGCCTTAGCCAGAT
SHE527: CCAGCCTGTAAAGCTTGAGG
SHE528: GGAATGCCTCATTTCCATGT
RA46: GGAGTGGAGTGGAGTGTGGAGG
RA45: GGACTGTGAAGGAGGTGCGAGG
SHE345: ACTGTGAAGTCCGAGGTCGT
SHE664: TGGGCAAGAACGCCCT
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1816 bp

Annealing
Temp. (Ta)
62 °C

1434 bp

60 °C

1765 bp

60 °C

910 bp

62 °C

1010 bp

64 °C

1490 bp

60 °C

362 bp

62 °C

310 bp

64 °C

313 bp

60 °C +
Enhancer

TABLE 2. RAI1 PRIMERS
Exon

E3
E3
E3
E3
E3
E3
E3
E3

E6

E3
E3
E3
E3
E6
E3
E3

Primers
SHE323: TCTGAGGCAAAAGGAAGTGG
SHE324: GACTGGGAATGCTGAGGAAA
SHE325: AAAGGCAGAAGCTGCAGAAC
SHE326: CAGTGCTGGCTTTTATGCTG
SHE327: TGTCAAGAACCTCGTGTCCA
SHE328: GGGAAACAGTCAAAAGCTGC
SHE329: TCTCGCTGGAGAACCACAG
SHE330: AACCAGCTCTGGACCTTTGA
SHE331: CACTCATCTGCACCAAGGAG
SHE332: ATGAAGGCCGACTTCCTTTT
SHE333: CCAAGAAGCTCCTCGACAAC
SHE334: TTCCGGCTCCTCTTCTTAGG
SHE335:AAACCGAGGCCTTCACATC
SHE336: CACACTCGGGACCTTTGAGT
SHE339: CTACCCTGAACACTGCCTCC
SHE340: AGAGGCAATGGAGACAGGAA
SHE345: ACTGTGAAGTCCGAGGTCGT
SHE346: GACTGGAAAGGGGACAAACA
SHE505: CCCGAGTCATGCAGTCTTTT
SHE506: TGGTAATGGAGGGTTTCCTG
SHE507: GGTCCAGAATCTTCATGCCTA
SHE508: CATGTCGTCAGGAGAGGTCA
SHE509: CTGCCAGGGTCAACAGCAAC
SHE510: CTCCTCCTCAGCTTCCAGGT
SHE511: AGGAGGACCTGGAAGCTGAG
SHE512: GTGACCGAAGGATCATGGAGC
SHE663: ACCCCAGCCGCGCTCT
SHE664: TGGGCAAGAACGCCCT
SHE666: TGCAGGCCTTGCTGTGT
SHE669: GTGTGACCTGCCTTAGCCAGAT
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Product Size

Anneal
ing
Temp.
(Ta)

770 bp

62 °C

875 bp

62/55
°C

777 bp

60 °C

904 bp

59 °C

1000 bp

60 °C

763 bp

59 °C

964 bp

60 °C

887 bp

60 °C

766 bp

60 °C +
PCR
Enhanc
er (no
BSA)

925 bp

60 °C

947 bp

62 °C

995 bp

64 °C

861 bp

66 °C

387 bp

52 °C

Internal Primer
Internal Primer

N/A
N/A

APPENDIX B

Revised genomic sequence of the RAI1 gene

Genomic sequence surrounding RAI1
Exon 3
gcgggggagc
tggcccgtct
cctccctccc
tcgagaaagg
atcacgccta
gctgctcgcc
cacgccctct
cctgcccaca
cagcagcccc
acagccacca
cttgatgaaa
gccctttcgg

aggcagggtg
gaatcgctca
tcccttcctt
tgtggtttcc
gagaattaca
aaggactatt
ggcactgcag
cagcaaggcc
tacccaggcc
cccccacagc
aagacagcag
actcactccc

gggaggtggg
tcctctgccc
tttcttttca
atggcaaaca
ggcagccgag
ataacccgca
ccgcggtggc
tgcaggggag
gctatgctgg
cgcagccact
tgccccccag
tgcacgtcca

tgggcgggcg
cctccctgcc
cagataacca
acagaactac
tcaggccggg
gccttacccg
cgccgacaag
gccggctttc
tgaggagagc
acctgcaggg
caggcagtat
gcagccaccg

102

ctttctgagg
catcctcccc
gcccgagtca
cagcagacct
ctaagctgcg
agctatgagg
taccaccgag
cctggctacg
cttcaggctt
gtggccaagt
gcagagcagg
ccgccccagc

caaaaggaag
tccctccttc
tgcagtcttt
cgcaggaaac
accggcagcg
gtggcgctgg
gcagcaaggc
gcgtccagga
ggggggcccc
atgatgagaa
gcgcccaggt
agcccctggc

SHE323
start E3/SHE505

SNP G269C/SHE666
253del119
SNP C493A

ataccccaag
ccagggtacc
ctctgtccag
cagccccatg
aatcttcatg
cagcagcagc
taccaaaacc
gacgcagccg
tcacccgccc
ccaaacctgg
gggatcactg
agctctgtgg
aacctgctgt
tctccaacac
tcaagaacct
ggagcggcta
cacagtccac
tggagcgcag
actcgaaggc
ccaccaaatc
ccaagttcgt
aggacctggc
cttgggctga
accacagcgc
aggccctgcc
ggctgtttga
ctctctcctt
cttttgactg
cctggccaga
ttaccaaggg
atgaggcttc

ctccaaaggc
cactttcctc
ggtggtgggc
acaggccgct
cctaccagtc
agcagcagca
tcgccaagta
tccggacccc
gctccgtggg
agaactttcc
accacagcca
acacccaggc
cggatctcag
cgtccagcag
cgtgtccagg
ctcagccgag
gcatgcggag
cttcctctac
caagcccgag
tgacgactcc
ggcgggtgag
ctccgagatc
agcacccagc
ctgcctggac
cgactccttg
agacccttcc
tggtaccaag
tttcccggac
ggaaaacctg
cctggagcag
ggcctgcctg

agaagctgca gaacgacatt gcctcccctc tgcccttccc SHE325
agcattccca gtccttcccc acctcctcca cctactcctc SHE324
agggggcccac tcctataaga gttgcacagc accgactgcc
gactgccagc tccagcctgg ccccggggca gcgggtccag SHE507F
gggccgcctc agctatgacc agcagcagca gcagcagcag SNP G837A
agcccttcag agccggcacc atgcccagga aaccctccat SHE506R/Poly#
tcagcactac gggcagcaag gccagggcta ctgccagccg
agagcagtac taccagacct tcagccccag ctccagccac
ccgctcacct tcctacagtt ccacaccgtc gccgctgatg
ctacagccag cagccgctca gcaccggggc cttccccgca 1119delC
cttcatgccc ctgctcaatc cctccccaac ggatgccacc
tggcaactgc aagccccttc agaaggacaa gctccctgag
cctgcagagcc tcacggcgct gacctcacag gtggagaaca
ctgctgctct ccaaggctgc tgtgccgcag aagaaaggtg SHE327
accccagagc agcataaaag ccagcactgc agccccgaag SHE326/1449delC
cccgcaggca caccgctgtc agagccgccg agcagcacgc
ccgcaggagg ccgactacct gagcggctcc gaggacccac
tgcaaccagg cccgtggcag ccctgccagg gtcaacagca SHE509F
tccgtgtcca cctgttctgt gacctctcct gacgacatgt SHE508R
ttccagagcc tacacggcag tctgccgctc gacagcttct
cgggactgtc cgcggctgct gctcagcgcc ctggcacagg
ctggggctgc aggaagccat cggtgagaag gccgacaaag
ctggtcaagg acagcagcaa gccacccttc tcgctggaga SHE329
tctgtggcca agagtgcgtg gccccggcct ggggagccgg SNP G1992A
cagctggaca agggcggcaa tgccaaggac ttcagcccag
gtggccttcg ctacgcctga ccccaaaaag acaactggtc
cccacccttg gggttcctgc tccagacccc actacagcag SHE328
acaaccgctg ccagctcagc ggacagcgcc aacccctttg
ggggatgctt gtcccaggtg gggattgcac cctggcgagc
ggtgggaagg cctcagatgg catcagcaaa ggggacaccc
ggcttccagg aggaggaccc ccctggggag aaggtggcct
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cgttgcccgg
tgctgcagtg
gttccaccgc
tggaagctga
ctggcatgca
aggaggtgct
tcatcctgct
ctctgtcaca
ccaccacctc
ccatcgcaaa
gggggctgcc
tgctccctga
gccggggggc
agccccgcac
ggggcaagca
ctgcctccag
gctccaagac
tccttcggtc
agggccggct
ccacattcaa
tccccaaacc
agtcggcctt
gcagcagcag
gttcccccac
atggcgagcc
cctctcgggc
ggggcctgaa
catgtaaagc
accgtgggct
tgggcaccgg
acagatcctt

ggacttcaag
ccccgaggtg
cgacttcggg
ggaggagtac
ggacccgctg
ggactccaag
gggccctaca
catgaagcca
ggacgcctct
gaaagagcct
cgaggccgag
atcctgcaca
ctcggaaggg
gcccggaccc
gcgagccgcc
ccccagcaac
caaggagaca
acgcaccaaa
ccccaactgc
ggtctccagc
tggtgcaggc
catggcgccg
cagcaacgcc
cctcttcaag
tgccacaaag
agccttccag
gctggaagcc
gccaggggcc
caagggtgct
gcagaagctc
aaaaggcaaa

caggaggagg
gccaaggctg
gacctcccac
tcctccctat
tcacccaagg
gccggctggg
gtgggcaccg
ggtgaagagg
ctggcccaga
gtgccacggg
gactccccat
gggccccccc
ctccccagga
ccaggcctga
ttcaagtcgg
ccggccgccc
gactcaccca
acccaggaga
cgtgccacca
agcccccaga
agcaagctct
gtccccacca
agtggcaatg
aggatgtctt
ctcccacccc
ggggccatga
atcgtgcaga
tctcctggta
gggggcagcc
ccaacttctg
ctcatgaaca

tgggtggggt
accggtggct
tgctgccacc
gtgagctcct
ccccactcat
gctctccgtg
agtcaaaggt
ggcctgatgg
agcccaacaa
gcaaaagctt
gcagggcacc
agggacagat
tgtgtactcg
ccaccacccc
gcaagcgggt
tgcctgtggc
gcacgcctgg
tcttccactc
agaagctcct
aggagggcag
ctgaccggcc
agaagcggaa
ggggagatgg
ctcccaagaa
cggagacccc
agaccaaggt
agatcacctc
atcctctgag
cagtgggggt
gggctgatcc
gtaagaaact
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gaaggaggag
ggaggacagc
caccagcagg
gggcagcccc
ctgcaccaag
ccacctctca
ccagagctgg
ggagcgagct
gcctgctgtg
acggagccgt
agtgctgccc
ggaaggggct
ttctctcacg
tgcaccccca
ggggaagccc
ctccgacagc
caaggaccag
caagcggcgg
cgacaacagc
ggtgagccag
cctccatgcg
cctggtcttg
gaaggaggag
agccaagccc
cgatgcctgc
gctgccaccc
gcccagcctc
cccatccctt
ggaagaaggc
gttatgcaga
gtcttctact

gcaggtgggc
cggcactgct
aaggaggacc
gagcagaggc
gaggaggtgg
ggggagtccg
tttgagtcct
ccaggggatt
cccgaggcgc
cgggtgcacc
aaagacctct
ggagccccag
gccctgagtg
gacaaactgg
tcacccaagg
agcccgatgg
cgctccatga
aggccctctg
cacttgcccg
cgggcaaggg
ctcaaaagga
cggagccgca
aggcctgagg
accaagggca
ctcaagctcg
cggaagggcc
aagaagttcg
tccgacaaag
ctggtaaatg
aatccaacca
gactgtttca

SHE511F
SHE510
SHE331
2773del29/SNP G2773A
SHE330
C2878T Non
2966delAAGA
3103delC/3103insC
SNP G3183A
SNP C3357T
SHE512R
SHE513F
SHE333
SHE332
3801delC

SHE515F
SHE514R

aaaccgaggc cttcacatcc
agaagaggag ccggaaaggc
aagcggccct atcttggccc
caaggggcca gtgaggacaa
ggcctggcct cccagccccc
cagccaggcc acaccaacta
gccaagaaca ccacctcttc
gtgctgcccc tggatcccgc
cggctgaggt cagacagccg
gacgcgttca ccaccatatg
aggaagcctt cctcctctgc
gccggggcct ccctggccac
cccctctcct ccacgatgca
cttgtttgct gcctctgcca
ccctactacc ctgaacactg
ccagaaggca cctgtgagga
SNP-A5175C/A5178T
tgtgcagctg ccgccactgc
aagcagggcc cactgcgcac
tgctgtgatg gccgggagga
catgagtgca gcaaggaggc
atgaggcctg tgccgtgtgg
tgcaggaggc catgaaggtg
agtgtggggt tccaaaggac
acagtgtggg ccaaatgtgt
ggggtgtgtg ggggaagtgg
tgtcccagga gacttcccgc
ctggcatctt caggctccag
cggagatgcc aaggcccaga
gggcggtgca agagcaagtt
gctaagggct caggaagacc

ccggaggccc
cgggcagggg
ggctctgctc
ctctggtgga
ggagggcagg
cagcagctat
accctgtaag
agagcctgaa
gacccccgcc
cactgttgtc
ctcctcttcc
actccctgga
cttggggcct
aaacccggcc
cctccccaaa
ggcctcgctg

tgcagcctgg
cccnatggac
ctgactcccc
ggaggcaaga
ccctgccagc
tccaagcgga
gggcgtgcca
atccgcctca
ttctcaccct
aactcccctg
tcatcctcgt
ggctccatcc
gtggtttcca
aacttcaagg
aagaagccaa
ccgcttgaga

ggggactgcc
tctccaaagg
gagacagggc
agccaaagat
cccagacaag
agcgcctcac
agcgacgacg
agtacatttc
tcgtgcgggt
gagatgcgcc
cctcgttctc
tgcagccgcg
aggccctgag
accttgggga
aactcaagga
gaacactcaa

cgggaagccc
cagtgcccgg
tgggggcgag
tccggcagag
accggcggcg
gccgtggaca
aggcaggcag
ctgcagtctc
aggcacccat
cggggcccgt
ccccacccag
gaacacgagg
gcccaccctc
ctctctggcg

cccaggcctg
ggcctgtccc
gaggcagccc
cccggcgggg
tctacctggt
tggtaagagg
gcagtcgggg
gggacaatct
ctggctaagg
atgcccagcc
aatccactgg
actcccaaga
tgttcctgtc
acacaggctt

acggcccagc tgacccggcc 5265delC
ggaggctgca gagctgctac SNP G5334A
cagccgacaa gggtcgcaaa
aggcccaggag cactgggtgc G5423A Mis
ggccgggaag ctctttgggc
ccagcccagc cagggtgggg end E3
agccccttgt ttctagtgct
gcagagtcct gagcctctct
caggtcacac tcacctaccc SHE669
accgccactc tcccactcac
gcccctcccc atgctgtcac
ttgaacatca gggctgcccc
tccattgcct ctgggatgaa SHE340/SHE668
ggtgcatgga cccagtcaca
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ctggcgccta
cccgctggag
cagtggcaca
ggaggagctg
ggcacagaaa
tcggggccgg
acagcagcag
ctcttgcaag
ggagaagcga
caagccccac
cttggatgca
gccctccttg
tacctcttgc
cctctgtggg
gaaggtgcgg
aggtcccgag

SHE335/SNP T4311C
SHE334
SNP G4512T
SNP C4530T
A4685GMis/4649delC

4933delGCCG
SHE516R
SHE339/SHE667
SHE336

gggttcctcc ctctgcagga cagtccatgg ggtcacacag tcacaacagg cagggcgggg
cagatccaga ccctctcacc attggctctg agaccagctt tggaagccat agtcactgag
Exon 4
gagtagctgg
caccatgttg
tcccagagtg
ttgagggctg
tccagctgcc
taccactacc
gagcccatcc
catctcactc
cctagacctc

gactacaggc
cccaggctgg
ctgggattac
ggctccaact
aagaagccgg
cgtgtgccag
aagcagtcca
ttcagtttcc
tgctgggcaa

acacaccacc
tatcaaactc
aggcatgagc
ggagactcac
ggccaccatt
cgatgcaggt
gggggaccct
ctcctctctt
tgccagggac

aaccctcact
ctggactcag
cactgcacct
ctgcctttcc
gggtgctgcc
acgagcccgc
ccctgggcac
gccccagcaa
atggaaatga

attttttgta
gcgatcctcc
ggcctaccag
tttctcttca
acaaaggatg
ccaggaacag
agctccccaa
ttcttttatc
ggcattcccc

gagacagttt
caccttggcc
cctgtaaagc
tcagatgtgt
cctccacacc
gagggcattg
acccaggccc
cttctgtctg
aggcacctgc

Exon 5
caagacaaga
aaggcgggag
actcaggggg
gccgcacccg
ctctttgaaa
tgcagacaaa
ttggtcacag
gtaggggacc
gcacctcctt
aggggaggga
ctgtccactt
gggctggagg
gggcaggcgg

tcacacaggc
ggagggaggg
aaaagctctc
cgccgtggag
agagcccctg
accccacagc
gttgcatatt
acagtgtttt
cacagtcccc
gctctccccg
gcgcgccgcc
gcgtccctgg
gggcgcggga

cagtctctta
actgagggac
cgcggaggag
tggagtggag
cagtctggag
tgtggggccc
catcgaagag
gtagggcgag
tgggccccct
cccaccccca
gccgccgaaa
gacggcctcc
cggtggcacg

ggaggcagtg
tgcctcaagt
gtgaggtgag
tgtggagggt
cctcgcgggc
ccaccctgtc
aacttttctt
gggtgtcaag
tggctgcgca
ggagcccccg
acccgcaggc
ctgcagctcc
gagctgaagg

acaagtgtgg
gaggaggggc
tcaagactgc
tttgtgcaga
agtgcggctc
ctaaccaccg
tgaaatgtcc
cgggagagga
gccccgcagg
ccgccgtcca
gtcggggcat
ccaagatagg
cgaaggtgaa

ctggcagagt
ggcacgtgga
caggccaggg
atctgattaa RA46
ccctcctggc
aaacttctct
caaacataag E5
gccccacctc RA45
gcccagccct
gctcaggtcc
gggcagccag
tgacagagtg
ggtgaagctg
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SHE527/674
E4
SNP T5601C
E4
SHE528/675

Exon 6 and some 3'UTR
gcggagaccc
actgggggcg
tcttttgcag
cctgcccgcc
ctcccagcgc
ctagggctca
ccggaaccgg
agcccgcgga
tttgtcctgg
ggtgctgccg
ggggtcgaaa
ggagaaagga
gaacaaaccg
tgcggttcgg
ccgagtgtgg
accccacccc
ccggctccgg

cagccgcgct
gggcctatgg
aggctgccgt
cgccgccgaa
tggtccagag
gacttgcggc
acggcacagg
gcggccagac
ggacactttc
ccaccccagt
cagtactgga
agcctttctg
tgcggaacgc
gcaaagccgg
gcgggactgg
tggagcccag
cggacgcgcg

ctggggtcgc
actgtgaagt
agtaatccac
ggagaggagc
ccgatccttg
cccgggttgg
gcgttcttgc
tccccggggc
cctctggaat
cggtcgtggc
agaggcggag
agagcgggct
gtccaggggc
ggtagacctg
gacacccttt
cctgggagcg
accgttgtgc

ctgggtctgg
ccgaggtcgt
cccaacggcc
cgcctgcgca
atccgggtcc
gaggaaaacc
ccaccccagg
gctcagcctc
ctcaagacga
gtgcagctgg
ggcggctcct
aggccggcac
cttcccgccc
ggctatgctc
ggcctctgtt
caaaacccaa
accaccaggg
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ggcttaggcg
cggtaactgg
ggaggagccg
gcccccgggc
cggatcgtgg
cgttccggag
ggccaggctt
cggcgagggt
cgtggcacac
gagccctggg
agctccgtgg
tggagaggcc
agcctttgcc
agttaggggt
tgtccccttt
gaagcggcca
accgccgcgc

gggggcccac
cgggcgggcgSHE345/C(5710-49)T
ccggagcccg E6
ctttgagctg UTR
atccggccgc
ccgcctgctc
gcggaggggg SHE664
gggagacggc
attccacgtg
cttgggggtg
actaggcggg
ggagcctttg
agatctctcg
tgcgggatcc UTR
ccagtcctcc SHE346
gaacgcacct
ctactctgca

APPENDIX C

cDNA sequence of zebrafish rai1 gene
atgcagt ccttcagaga gcggagtggt ttccatagcg accagcactg
ctaccagcag gaaccccaag aattaccgcg cctcgagagc tacagacatc
gtccagacag ggctacgagc cacacgcttt agcttctgcc gggatgtcaa
taaagactgt tacggacagc agaactatcc tgtctacacc agcgccacac
accatacaga ggaggcaaaa ctccaaacca gcatctacag gcgggctaca
gggcaccgga tacacggccc agtacatgag cgaaggtcac ctgcagcaga
gtcagctcag atgacccagt tcgagcagga catggtgggt cgtctggagt
gcagtaccta gagcagaaca tgctagctat ctctcaaagt cagtgccatc
gtcctccgcc ccagtctaca ccagtcccca tcagcaggga atcccaccca
atctccttta atgtacccac aaggccacat gcatttccct cagcactcgc
ttcaccttca tcggcctata tggacaaatg taatacagcg tcacatggct
tgggatacca cctaacgccc agtatggaag gcagctgagc aatcacagca
gagtggatac agacctcaga ataattacgg ttaccagcaa actccttcga
tgagcagggc tccctgcagg gcatgtctgg tacacaggag agccttcaga
ctacaatcag acccagcaaa actactgcat aactgatatt tcagtaaggt
atactaccag acctgcagtc ctagttccag tcattcaccg gcgaggtctg
tccctcgtac aactccacac catcaccctt gatggcgaat gctgattcct
ccagcctccc atcaaccctg gggcttcatc atccacaggt ttgcagaatg
gctgatgccc cctcacaccc actcatcgtc cagtgtgaac cagacccaga
atcaatgaaa gaacgattct cagagaagct cctgaccaac cctagtttgt
tgccctaact tctcaggttg aaaacatctc caacaatgtc cagcagctgc
agctctcatg gcgagcaaaa agaccagtaa acgaaaccat cctaaaaagg
cagaggtcaa ctggaaggta tggatgagtc ttgtcctgaa aatcaacatg
gtctgatgct tacagcattc ccaggtccat gacagcagga ctgcaggagg
cagcagcacc gaggaccaga tggaaaggaa ctattattat tttggtcagg
aggacatacc cagacacact cccgtctcag ccttgacaca gtgtccacat
ctcggctgac gatgtctccg ttaggtcagg agactcagtt cgaagtctcc
ctcggaggat aatcttaact gtgaccccag agtacaaagg gcactgtctg
cgatagctct ctctgctgca ttagagatga gaggtctccc atcggcgtaa
tcctatgaaa caagagagtg attcaccacc agacataaaa cgttcagaga
ggagaacttt gaggagtcag catggaccga gaggatggct gatgaggaca
aagcaagccg tctgctgagc atgattgcaa aggagaggtc actgaaaaac
gctggaggat gagaaaggtc ctgctctttt tcagaaaata aataaaaccg
aggttactcc tatgaaacgg aagagaatat ctaccaaggg ctacaaaaca
ggagaaagaa aacacgacgg agatagactg ctttgctgaa ctcaatcaca
agacacagag ataaagacag agcattttaa atcagagcca caaaccagtg
aacggaagac tctcccagca attcagccac tgaactgtgt ttgccagaga
ctcaagcagt gagaattcgg tagagacccc aacatgcacc cttgagggac
ccttgaggag cagacttctg tcctctctca tacgtccact gaggtaggag
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attacagcca
cagcgggatc
agactaagaa
gtaaccacat
aatgggatga
ctgggtcatc
tccccgccca
acccggcgcc
aaacctcttc
acaaaggcta
gtctaaaaca
ggtctgggtt
aattccagta
cgccggaaca
tggggagatc
tccagtatgg
aacaaaatat
gcttctctgg
ggagtctcaa
tgctgtctga
gagaagatta
gtccttctcc
gaggatactc
aaaagggtca
gctccttaaa
agagtgtagc
aagaggagcc
cagctccaag
gcactcaaaa
aaaccgaaca
aagagaagtg
tgctggagga
aatatgattc
aatgtgacga
ttgaaatgcc
aagaagaaca
ctgcggacac
atgaaaagga

ttcaattctg
tccagacgtc
tgcagaaagc
tgacattgca
aacacctttg
gcctgactct
cactccaccc
tgcagtgact
cggtaagaaa
gcagctaagt
tattgtcgat
tacagagagt
ggtctcccct
aatagctgtc
atcaattaca
acctggcccc
taaatctggc
aaagcctggg
gtcaaagcca
gaacaaacag
ggacacacac
cacaattgtt
tacgctagac
atcacggaag
tactaagaca
tggaccttca
gccagatgaa
aaagaggaag
ccacattcca
tactttaact
tcagtgtccc
ggcaatggtt
agacattgca
gacaacgaac
acccgaaaac
gagcagcgat
actagctaaa
gagaagaaaa
acagaccgaa
caaggagcca
atcacttaaa
cgagaagaaa
gaagagacct
cttgcgccca
ctctatggac
cgctcaggct
caactcttca
aacgtgctgt
ctattatcct
caggcaaaac
gagtgtgtgt
caaaagagca
gctgctgatt
tgaaacaagt

acaagctcag
tgtggcacat
attgcccagg
cctcagactc
gctcaggcaa
cctcagttgc
tctcccaaga
ccctcagcca
catgtacggg
atagaaggag
cagatggaaa
ttaccatcac
caagacagaa
aagccaggtc
aaacctggtt
aagccaggtt
ccaaaatctg
tcagtaccag
attgtggcat
atgaagatga
tgtactcaag
ggtgttgtgg
agcagctgct
caaacaaaag
ccttcagcaa
aatctcgaat
gaggtggttt
aaaggaaggc
aagggaaaga
actgataccc
actaaaacca
cagaaaataa
ctagaagaat
gcccctgaga
acagaaattc
gctccagatg
cagagagcca
ggcactgaac
gtcttgccta
ccaaatgaag
aagaaacaag
aaaaagactg
aagatcaaga
gatctaagtg
gtcgcatctt
aggacaaaga
gtaatgctcc
ttatgtggaa
gaggactgca
agcaactgtg
gaggaggcca
attcgggaac
ttgcagagca
ctgcagagat

aggaggtcat
atgaggaggc
acacaccaca
acactgccaa
gggatcatca
caggcaagtc
aagcggacga
aaccagaggc
gcaggaggag
acactcaaac
ctgcccatca
ggatgtgcac
ggaaaccagg
caaaatcaaa
caaaatcagt
taaaatccac
ccactaaatc
gagagatact
cagtagctaa
aacaagatga
aacttaattt
ataccactaa
taaaatcatt
agaaactgac
tggtcatgca
tgcccaagca
ccaccaagag
aagatgaagt
gaaagagagg
ttcccactga
aatatttgcc
catccccagg
ccacgttaaa
tgcctcagaa
aaactccaag
taagcctgga
ttaaaaacaa
ctcaagaaaa
catctccacc
tatgcgtacc
aggaactctc
ggcccaaaaa
caaatgaact
acggaaaatc
catgcactat
gtgtacctaa
agggcccctt
agccagctaa
taccacgaaa
ccaacgagac
tccatcagga
tgtcgagaac
gacttagtgg
tacagatgga

caataataaa
ggaaaacatg
cagagacagc
gagtgacttc
catcgattgt
gatactgcac
ggatatggag
ttttacgcca
accaatgagc
tcccaatata
gaatgttagt
tcgctcctac
tgcaaaacct
tccaaaacct
tcctaaatcc
agggtccaaa
tggtccaaaa
tgctccaaag
aggccccggt
aaatgttcaa
gcaagatgtg
aggtgaaacc
agggagagag
tgaagaaaaa
ggatgttact
gaaggatgtc
aaaatgcagt
gaaggcacag
acaacgtttg
tgacatcagt
tcctcggaaa
gtccaaaaag
accagtgccg
ggagggcgaa
gaagaaaagg
tggtggaagt
ccacgagatg
catccccata
tccgccagaa
actaatgaaa
gaagagtcaa
aaagtgtgtg
gtctccaaca
ctctgtcaga
cgtcaacagg
tatcaaaaat
agttaacaaa
ttacagagag
aacgctgtca
ggagagtagt
aaaggcaaac
caggcccagt
agcgtctccc
ggccgaggaa
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acagagtcac
caacaagtaa
gaaaggaggt
tcagctctca
agtgatgcaa
tctgcaccat
ccaggaataa
tcttcacata
tcaactgcag
ccttcaagca
agtcaaacac
ggttcacaag
gctccaaaac
gcaccaaagc
gaggtcatgc
gaaagtccaa
actgcttcta
tcaaatcaaa
cgaccgaaag
acaactacag
accacagaat
gtggctccca
cagaagtcta
gaacaaaacg
gtggatcagt
tccacagatt
ttaccaacct
gattctccat
cttgtggaat
gacgtgccat
ggcaggggac
caacctgtaa
caggtaccag
agcacaatca
agaaagtggg
ctgattatca
catctgaagc
gtggagcaac
actcttgaac
cccaaacgcg
aaagaagacg
gatgccgtta
gtacaaggga
ccatacgtac
cccgaagaag
caagctgcaa
agcctatctg
ctcggggact
ttaacacaca
agcattgtga
gaagggcact
tcgcgaatga
cctgctggtg
aaagagcact

aggagtcttt
acacagaaac
cagtcatatg
atgagaaaac
aggtgctgga
cttgggctga
actgtcccag
caagaatgtt
gaataagaag
aaaccaccga
caaaacttgt
gtagcccaaa
caagctcaaa
atagtccaaa
ctagtgtaaa
agccttgtcc
aacccgcctc
acacagcaga
gaatcagtaa
aacataccaa
tagctttgga
ctttggagtg
tggtgttaag
atgataaatc
cgtgtaagac
cacttcaaca
cagaaaccaa
tagacatagt
cagtaagcac
ctgtacctcc
ttaaatatga
gtaaccaagc
atcaaaagga
gtacacaaga
ccactgtgga
acacaccgag
agcgaaagaa
cggagtctac
agacagagtg
gcaggcggcc
aaaacgcaat
aagttgtggt
cattatcaga
acatcgacag
agcagatgct
agacagggtc
acagatgtct
tgtgtggccc
ggagtgaatt
aaaacacaca
ccaggaggag
ggtttaaaag
tggagggcat
gggctcatga

agcgtgtgct
cgaggctgtt
ggtctgctgc
gggctgcacg

gtctggacca
cagaaagctg
ggctggaaga
tttgaagaag

ctggcatagt
cacatgcaaa
gctgtactca
aaaccttctc

cctggtggcg
atgctccgga
aagctaccat
tattcggtgt
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gataaactct
tgccaaggtg
tatatctgcg
ccgaaacaca

ttggactgac
aaggagcctc
ccaaagagtc
aggtaagtgt

IRB protocol used
Institutional review board (IRB) protocol for the SMS study
2004-present – Protocol number 3784, ―Molecular analysis of Smith-Magenis
syndrome.‖
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